Fusion protein comprising TGF-βRII extracellular region fragment, pharmaceutical composition thereof and use thereof

MYPI2025005064A0Undetermined Publication Date: 2024-08-20AKESO BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005064
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-20
Filing Date
2024-02-20
Publication Date
2024-08-20

AI Technical Summary

Technical Problem

In the existing technology, TGF-β receptor fusion proteins are prone to breakage and degradation, which affects the purity and quality uniformity of the drug, thereby affecting safety and effectiveness.

Method used

A fusion protein containing an anti-TIGIT antibody and a TGF-βRII extracellular region fragment was designed. By replacing or deleting specific amino acid sequences, the stability and binding activity of the fusion protein were improved, and the defect of easy breakage was overcome.

Benefits of technology

It achieves higher stability and purity, enhances the binding ability to TIGIT and TGF-β, has good anti-tumor drug potential, and effectively blocks immunosuppressive signals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025005064_DRAWING_001
    Figure PI2025005064_DRAWING_001
  • Figure PI2025005064_DRAWING_002
    Figure PI2025005064_DRAWING_002
  • Figure PI2025005064_DRAWING_003
    Figure PI2025005064_DRAWING_003
Patent Text Reader

Abstract

The present disclosure pertains to the fields of biology and pharmaceutics and relates to a fusion protein comprising a TGF-βRII extracellular region fragment, a pharmaceutical composition thereof, and use thereof. Specifically, the fusion protein of the present disclosure comprises: a first protein functional region targeting an immune checkpoint and a second protein functional region with TGF-β binding activity, wherein the second protein functional region is a variant of a TGF-βRII extracellular region fragment, and the variant of the TGF-βRII extracellular region fragment is: the first serine at the N-terminus of the TGF-βRII extracellular region fragment is replaced with alanine, glycine, or threonine, and / or a fragment comprising the amino acid sequence set forth in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular region fragment. The fusion protein of the present disclosure can simultaneously inhibit TIGIT and reduce TGF-β levels, demonstrating good potential for preparing anti-tumor drugs. Figure 45
Need to check novelty before this filing date? Find Prior Art

Description

Fusion protein containing TGF-βRII extracellular region fragment, pharmaceutical composition and use thereof Technical Field

[0001] The present invention belongs to the fields of biology and medicine, and relates to a fusion protein comprising a TGF-βRII extracellular region fragment, a pharmaceutical composition thereof and uses thereof. Background Art

[0002] The transforming growth factor-β (TGF-β) superfamily is a diverse class of cytokines, further divided into subfamilies including TGF-β, activins, inhibins, growth differentiation factors (GDFs), glial-derived neurotrophic factors (GDNFs), Nodal, Lefty, and anti-Müllerian hormone (AMH) (Table A). The three TGF-β subfamily proteins are designated TGF-β1, TGF-β2, and TGF-β3, with TGF-β1 being the most highly expressed isoform. After binding to receptors, TGF-β1, TGF-β2, and TGF-β3 mediate a series of biological reactions through Smad and non-Smad signaling pathways, including promoting epithelial-mesenchymal transitions (EMT), promoting tissue fibrosis, promoting angiogenesis, promoting tumor immune escape, and having dual effects of tumor suppression and promotion (J Massagué. TGFbeta in Cancer. [J]. Cell, 2008, 134(2): 215-230.).

[0003] TGF-β receptors (TGF-βR) are widely distributed on the surface of normal human cells and tumor cells, including three receptor superfamilies. The type I classical TGF-β receptor family includes ALK1-7, among which TGF-βRI (also written as TβRI) is also called ALK5; the type II classical TGF-β receptor family includes TGF-βRII (also written as TβRII), ActRII, ActRIIB, AMHRII and BMPRII; the type III TGF-β receptor superfamily includes Betaglycan (also known as TGF-βRIII) and Endoglin; among them, TGF-βRI, TGF-βRII, and TGF-βRIII can each bind to TGF-β1, TGF-β2, and TGF-β3 (Pawlak John B, Blobe Gerard C, TGF-βsuperfamily co-receptors in cancer. DevDyn, 2021). The TGF-β family and receptors are shown in Table A (based on a review by Carl-Henrik Heldin1 and Aristidis Moustakas. Cold Spring Harb Perspect Biol. 2016). TGF-βRI and TGF-βRII are serine / threonine protein kinase receptors. TGF-βRII is a key signal transducer in the TGF-β signaling pathway. It binds to TGF-β with high affinity and then forms a heterotetrameric receptor complex with the TGF-βRI dimer. TGF-βRII phosphorylates and activates TGF-βRI through autophosphorylation of TGF-βRII. Activated TGF-βRII phosphorylates downstream Smad pathway proteins, regulating the transcription and translation of downstream target genes and triggering disease-related biological responses. TGF-βRIII has a weaker affinity for TGF-β than TGF-βRI and TGF-βRII and lacks an intracellular domain, preventing it from accessing downstream signaling pathways. Its function is to capture TGF-β and present it to TGF-βRII. Other TGF-β receptors can also bind to TGF-β (Sang Xiaohong et al., Research progress on small molecule inhibitors targeting TGF-β and receptors [J]. Acta Pharmaceutica Sinica, 2019(9).).

[0004] Table A: TGF-β family and receptors

[0005] During tumor progression, tumor cells, mesenchymal fibroblasts, and other cells in the tumor microenvironment (TME) secrete large amounts of TGF-β, mediating immunosuppression. TGF-β inhibits the differentiation of naive T cells into Th1 cells, which mediate anti-tumor activity. T cells lacking TGF-βRⅡ exhibit enhanced Th1 responses (Eduard, Batlle, Joan, et al. Transforming Growth Factor-β Signaling in Immunity and Cancer. [J]. Immunity, 2019.). TGF-β decreases the expression of granzyme A, granzyme B, perforin, interferon-γ (IFN-γ), and FasL in effector T cells with tumor-killing activity, leading to immune escape of tumor cells. Tregs are key cells in the tumor microenvironment that mediate tumor immunosuppression and can inhibit the function of effector T cells with tumor-killing activity. TGF-β produced by tumor cells induces the emergence of a large number of Tregs in the TME, enhancing tolerance to tumor antigens and promoting tumor immune escape (Chen Dan, Ran Yan. Research progress on TGF-β regulation of tumor cells and tumor-associated immune cells [J]. Modern Medicine and Health, 2020, 36(09):1354-1358.). Currently in the clinical stage, the indications of antibody drugs targeting TGF-β molecules include melanoma, renal cell carcinoma, breast cancer, cervical cancer, advanced non-small cell lung cancer, prostate cancer, pancreatic ductal adenocarcinoma, advanced solid tumors, and metastatic solid tumors.

[0006] TIGIT (T cell Ig and ITIM domain, also known as WUCAM, Vstm3, VSIG9) is a member of the poliovirus receptor (PVR) / nectin family. TIGIT consists of an extracellular immunoglobulin variable region (IgV) domain, a type 1 transmembrane domain, and an intracellular domain with a classical immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoglobulin tyrosine tail (ITT) motif. TIGIT is highly expressed in lymphocytes, especially in effector and regulatory CD4 + T cells (Treg cells), follicular helper CD4 + T cells, effector CD8 +T cells and natural killer cells (NK cells) (Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J]. Nature immunology, 2009, 10(1): 48).

[0007] CD155 (also known as PVR, Necl5 or Tage4), CD112 (also known as PVRL2 / nectin 2) and CD113 (also known as PVRL3) are ligands bound by TIGIT (Martinet L, Smyth M J. Balancing natural killer cell activation through paired receptors [J]. Nature Reviews Immunology, 2015, 15 (4): 243-254.), among which CD155 is a high-affinity ligand for TIGIT. In NK cells, TIGIT binding ligands CD155 and CD112 can inhibit the killing effect of NK cells on cells with high expression of CD155 and CD112 (Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity [J]. Proceedings of the National Academy of Sciences, 2009, 106 (42): 17858-17863). It has been reported that blocking PD-1 and TIGIT at the same time can enhance the killing effect of CD8+T cells (Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+T cell effector function [J]. Cancer cell, 2014, 26 (6): 923-937).The latest research found that TIGIT, as an immune checkpoint of NK cells, can lead to NK cell exhaustion during tumor development. It has also been shown that anti-TIGIT monoclonal antibodies can reverse NK cell exhaustion and be used for immunotherapy of various tumors such as non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, etc. (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J]. Nature immunology, 2018, 19(7): 723-732).

[0008] In addition, it has been reported that TIGIT blockade, alone or in combination with PD-1 blockade and CD96 blockade, can significantly reduce the growth of B16 melanoma in wild-type and CD155- / - mouse models (Li XY, Das I, Lepletier A, et al..Cd155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest 2018;128:2613-25). CD112R blockade, alone or in combination with TIGIT blockade and / or PD-1 blockade, can increase the ability of TILs to produce cytokines in ovarian, endometrial, and lung tumors (Whelan S, Ophir E, Kotturi MF, et al..PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+T-cell Function. Cancer Immunol Res 2019;7:257-68).

[0009] Currently, there is still a need to develop new fusion proteins comprising TGF-β receptors, especially TGF-βRII extracellular domain fragments, such as fusion proteins comprising anti-TIGIT antibodies.

[0010] Summary of the Invention

[0011] After in-depth research and creative work, the inventors have produced a fusion protein comprising an anti-TIGIT antibody and TGF-βR. Surprisingly, the inventors discovered that this fusion protein can effectively bind to both TIGIT and TGF-β simultaneously, even overcoming the drawbacks of being susceptible to breakage or degradation, and has the potential to be used in the preparation of anti-tumor drugs. The following invention is provided:

[0012] One aspect of the present invention relates to a fusion protein comprising:

[0013] Targeting the first protein domain of the immune checkpoint, and

[0014] The second protein functional domain has TGF-β binding activity,

[0015] in,

[0016] The second protein functional region is a variant of the TGF-βRII extracellular region fragment, and the variant of the TGF-βRII extracellular region fragment is:

[0017] The first serine at the N-terminus of the TGF-βRII extracellular region fragment is replaced with alanine, glycine or threonine; and / or, the fragment containing the amino acid sequence shown in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular region fragment.

[0018] In some embodiments of the present invention, the fusion protein, wherein the amino acid sequence of the TGF-βRII extracellular domain fragment is as shown in SEQ ID NO: 33 or SEQ ID NO: 37.

[0019] In some embodiments of the present invention, the fusion protein, wherein the deleted fragment containing the amino acid sequence shown in SEQ ID NO: 59, has an amino acid sequence as shown in any one of SEQ ID NO: 59 to SEQ ID NO: 65.

[0020] In some embodiments of the present invention, the fusion protein, wherein,

[0021] The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO: 49 to SEQ ID NO: 58.

[0022] In some embodiments of the present invention, the fusion protein, wherein the immune checkpoint is one or more selected from PD-1, PD-L1, CTLA-4, LAG3 and TIGIT.

[0023] In some embodiments of the present invention, in the fusion protein, the first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof.

[0024] In some embodiments of the present invention, in the fusion protein, the first protein functional region is an anti-PD-L1 antibody or an antigen-binding fragment thereof.

[0025] In some embodiments of the present invention, in the fusion protein, the first protein functional region is an anti-CTLA-4 antibody or an antigen-binding fragment thereof.

[0026] In some embodiments of the present invention, in the fusion protein, the first protein functional region is an anti-LAG3 antibody or an antigen-binding fragment thereof.

[0027] In some embodiments of the present invention, the fusion protein, wherein the first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof.

[0028] In some embodiments of the present invention, the fusion protein, wherein,

[0029] The anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein:

[0030] The amino acid sequence of HCDR1 is shown in SEQ ID NO: 3, the amino acid sequence of HCDR2 is shown in SEQ ID NO: 4, and the amino acid sequence of HCDR3 is shown in SEQ ID NO: 5, and

[0031] The amino acid sequence of LCDR1 is shown in SEQ ID NO: 8, the amino acid sequence of LCDR2 is shown in SEQ ID NO: 9, and the amino acid sequence of LCDR3 is shown in SEQ ID NO: 10.

[0032] In some embodiments of the present invention, the fusion protein, wherein the amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is selected from SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17; and

[0033] The amino acid sequence of the light chain variable region of the anti-TIGIT antibody is selected from SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and SEQ ID NO:25.

[0034] In some embodiments of the present invention, the fusion protein, wherein,

[0035] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6;

[0036] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 11, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 19;

[0037] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 17, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 19;

[0038] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 21;

[0039] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 23;

[0040] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 21;

[0041] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 23;

[0042] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 11, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 25; or

[0043] The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 17, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 25.

[0044] In some embodiments of the present invention, the fusion protein, wherein the anti-TIGIT antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementary determining region fragment, single-chain antibody, humanized antibody, chimeric antibody or diabody.

[0045] In some embodiments of the present invention, the fusion protein, wherein,

[0046] The anti-TIGIT antibody includes non-CDR regions, and the non-CDR regions are from a species other than murine, such as a human antibody.

[0047] In some embodiments of the present invention, in the fusion protein, the heavy chain constant region of the anti-TIGIT antibody is Ig gamma-1 chain C region or Ig gamma-4 chain C region; and the light chain constant region is Ig kappa chain C region.

[0048] In some embodiments of the present invention, the fusion protein has a stronger ability to bind to the ligand CD155-hFc-Biotin than the control antibody RG6058 (hG4).

[0049] In some embodiments of the present invention, the fusion protein, wherein the fusion protein has an EC value of less than 0.08 nM or less than 0.10 nM. 50 Binds to TIGIT-mFc; preferably, the EC 50 Detected by indirect ELISA method.

[0050] In some embodiments of the present invention, the fusion protein, wherein the fusion protein has an EC value of less than 0.3 nM, less than 0.4 nM, less than 0.5 nM or less than 0.6 50 Binds to TGF-β1, TGF-β2 and / or TGF-β3; preferably, the EC 50 Detected by indirect ELISA method.

[0051] In some embodiments of the present invention, the fusion protein, wherein the anti-TIGIT antibody is an antibody produced by the hybridoma cell line LT019, and the hybridoma cell line LT019 is deposited in the China Center for Type Culture Collection (CCTCC) with a deposit number of CCTCC NO: C2020208.

[0052] In some embodiments of the present invention, the fusion protein, wherein, according to the EU numbering system,

[0053] When the heavy chain constant region of the anti-TIGIT antibody is IgG1, the heavy chain constant region has one of the following mutation combinations:

[0054] L234A and L235A;

[0055] L234A and G237A;

[0056] L235A and G237A; or

[0057] L234A, L235A, G237A;

[0058] When the heavy chain constant region of the anti-TIGIT antibody is IgG4, the heavy chain constant region has one of the following mutation combinations:

[0059] F234A and L235A;

[0060] F234A and G237A;

[0061] L235A and G237A; or

[0062] F234A, L235A, G237A.

[0063] In some embodiments of the present invention, the fusion protein:

[0064] The amino acid sequence of the heavy chain of the anti-TIGIT antibody is shown in SEQ ID NO: 27 or SEQ ID NO: 31, and the amino acid sequence of its light chain is shown in SEQ ID NO: 29.

[0065] In some embodiments of the present invention, in the fusion protein, the first protein functional region and the second protein functional region are directly connected or connected through a connecting fragment.

[0066] In some embodiments of the present invention, the fusion protein, wherein the connecting fragment is a polypeptide as shown in SEQ ID NO: 69 or SEQ ID NO: 70, or a polypeptide obtained by concatenating multiple (e.g., 2, 3, 4, 5, or 6) polypeptides as shown in SEQ ID NO: 69, or a polypeptide obtained by concatenating multiple (e.g., 2, 3, 4, or 5) polypeptides as shown in SEQ ID NO: 69 and further concatenating the polypeptide as shown in SEQ ID NO: 70;

[0067] Preferably, the amino acid sequence of the connecting fragment is shown as SEQ ID NO:44 or SEQ ID NO:66.

[0068] In some embodiments of the present invention, in the fusion protein, the first protein functional region and the second protein functional region are independently 1, 2 or more.

[0069] In some embodiments of the present invention, in the fusion protein, the second protein functional region is connected to the C-terminus of the first protein functional region.

[0070] In some embodiments of the present invention, the fusion protein, wherein the second protein functional region is connected to the C-terminus of the heavy chain of the anti-TIGIT antibody.

[0071] The present invention relates to a fusion protein comprising:

[0072] Targeting the first protein domain of TIGIT, and

[0073] A second protein functional domain having TGF-β binding activity;

[0074] in,

[0075] The number of the first protein functional region is one, and the number of the second protein functional region is two;

[0076] The first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof, and the second protein functional region is a variant of the TGF-βRII extracellular domain fragment;

[0077] The amino acid sequence of the heavy chain of the anti-TIGIT antibody is shown in SEQ ID NO: 27 or SEQ ID NO: 31, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 29;

[0078] The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO: 49 to SEQ ID NO: 58;

[0079] The second protein functional region is connected to the C-terminus of the heavy chain of the anti-TIGIT antibody through a connecting fragment;

[0080] Preferably, the amino acid sequence of the connecting fragment is shown as SEQ ID NO:44 or SEQ ID NO:66.

[0081] Without being bound by theory, some TGF-βR fusion proteins are unstable and may break down, resulting in an incomplete fusion protein structure. This creates challenges in production and quality control, affecting the purity and uniformity of the fusion protein, and subsequently raising concerns about drug safety and efficacy. For practical production and application, it is necessary to develop more stable antibody / TGF-βR fusion proteins.

[0082] In some embodiments of the present invention, the fusion protein, compared to a fusion protein using a TGF-βRII extracellular domain fragment (e.g., SEQ ID NO: 33 or SEQ ID NO: 37), has less fragmentation and / or degradation when recombinantly expressed.

[0083] In some embodiments of the present invention, the fusion protein is used to treat and / or prevent tumors;

[0084] Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell carcinoma, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma;

[0085] Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

[0086] In a broad sense, the fusion protein of the present invention can also be referred to as an antibody.

[0087] Another aspect of the present invention relates to an isolated nucleic acid molecule encoding the fusion protein of any one of the present invention.

[0088] Yet another aspect of the present invention relates to a vector comprising the isolated nucleic acid molecule of the present invention.

[0089] Yet another aspect of the present invention relates to a host cell comprising the isolated nucleic acid molecule of the present invention, or the vector of the present invention.

[0090] Another aspect of the present invention relates to a conjugate, which includes a fusion protein portion and a coupling portion, wherein the fusion protein portion is the fusion protein described in any one of the present invention, and the coupling portion is a detectable label; preferably, the coupling portion is a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0091] In some embodiments of the present invention, the conjugate is used to treat and / or prevent tumors;

[0092] Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell carcinoma, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma;

[0093] Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

[0094] Another aspect of the present invention relates to the use of the fusion protein of the present invention or the conjugate of the present invention in preparing a kit for detecting the presence or level of TIGIT and / or TGF-β in a sample.

[0095] Another aspect of the present invention relates to a pharmaceutical composition comprising the fusion protein or the conjugate of any one of the present invention; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients (such as carriers and / or excipients); optionally, the pharmaceutical composition further comprises one or more tumor chemotherapy drugs.

[0096] In some embodiments of the present invention, the pharmaceutical composition, wherein the unit dose of the pharmaceutical composition, calculated according to the mass of the fusion protein therein, is 100mg-1500mg, 200mg-1000mg, 200mg-800mg, 300mg-600mg, 400mg-500mg or 450mg.

[0097] In some embodiments of the present invention, the pharmaceutical composition is an injection.

[0098] In some embodiments of the present invention, the pharmaceutical composition, wherein the fusion protein or the conjugate of the present invention is the sole active ingredient.

[0099] In some embodiments of the present invention, the pharmaceutical composition is composed of the fusion protein or the conjugate of any one of the present invention and one or more pharmaceutically acceptable excipients.

[0100] Another aspect of the present invention relates to use of the fusion protein or conjugate of any one of the present invention in the preparation of a drug for treating and / or preventing tumors;

[0101] Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell carcinoma, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma;

[0102] Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

[0103] Another aspect of the present invention relates to a method for treating and / or preventing tumors, comprising the step of administering to a subject in need thereof an effective amount of the fusion protein or conjugate of any one of the present invention;

[0104] Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell carcinoma, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma;

[0105] Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

[0106] In some embodiments of the present invention, the method, wherein the step of administering an effective amount of the fusion protein of any one of the present invention or the conjugate of the present invention to a subject in need is before or after surgical treatment, and / or before or after radiotherapy.

[0107] In some embodiments of the present invention, the method, wherein,

[0108] The single dosage of the fusion protein of the present invention is 0.1-100 mg per kilogram of body weight, preferably 1-10 mg; alternatively, the single dosage of the fusion protein of the present invention is 10-1000 mg per subject, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg;

[0109] Preferably, the drug is administered once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks or 3 weeks;

[0110] Preferably, the administration is by intravenous drip or intravenous injection.

[0111] It should be noted that the dosage may vary depending on the type and severity of the symptoms to be treated. In addition, those skilled in the art will understand that for any particular patient, the specific dosage regimen should be adjusted over time based on the patient's needs and the physician's professional evaluation; the dosage ranges given herein are for illustrative purposes only and do not limit the use or scope of the fusion protein or pharmaceutical composition of the present invention.

[0112] In the present invention, the subject may be a mammal, such as a human.

[0113] Another aspect of the present invention relates to a variant of the TGF-βRII extracellular domain fragment, which is:

[0114] The first serine at the N-terminus of the TGF-βRII extracellular domain is replaced with alanine, glycine or threonine; or

[0115] The fragment containing the amino acid sequence shown in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular domain fragment;

[0116] Preferably, the amino acid sequence of the TGF-βRII extracellular region fragment is shown as SEQ ID NO: 33 or SEQ ID NO: 37.

[0117] In some embodiments of the present invention, the variant of the TGF-βRII extracellular region fragment, wherein the deleted fragment comprising the amino acid sequence shown in SEQ ID NO:59, has an amino acid sequence as shown in any one of SEQ ID NO:59 to SEQ ID NO:65.

[0118] In some embodiments of the present invention, the variant of the TGF-βRII extracellular domain fragment, wherein,

[0119] The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO: 49 to SEQ ID NO: 58.

[0120] The variable regions of the light and heavy chains determine antigen binding; each chain's variable region contains three hypervariable regions, called complementarity-determining regions (CDRs). The heavy chain (H) CDRs comprise HCDR1, HCDR2, and HCDR3, while the light chain (L) CDRs comprise LCDR1, LCDR2, and LCDR3. In this invention, CDRs are defined using the IMGT numbering system. See Ehrenmann F, Kaas Q, Lefranc MP. IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF, and MhcSF [J]. Nucleic acids research, 2009; 38(suppl_1): D301-D307.

[0121] The amino acid sequence of the CDR of the following monoclonal antibody sequence was analyzed using techniques well known to those skilled in the art, for example according to the IMGT definition, and the results are as follows:

[0122] HCDR and LCDR of mouse TIGIT monoclonal antibody

[0123] HCDR1:GHSFTSDYA(SEQ ID NO:3)

[0124] HCDR2: ISYSDST (SEQ ID NO: 4)

[0125] HCDR3:ARLDYGNYGGAMDY(SEQIDNO:5)

[0126] LCDR1: QHVSTA (SEQ ID NO: 8)

[0127] LCDR2: SAS (SEQ ID NO: 9)

[0128] LCDR3:QQHYITPWT (SEQ ID NO: 10)

[0129] The three HCDRs and three LCDRs of the humanized TIGIT monoclonal antibody are the same as those of the mouse TIGIT monoclonal antibody.

[0130] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0131] As used herein, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.

[0132] As used herein, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be further subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antibody binding site. The assignment of amino acids to regions or domains follows Bethesda Md, Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1987; 196: 901-917; Chothia et al. Nature 1989; 342: 878-883, or the IMGT numbering system definition, see Ehrenmann F, Kaas Q, Lefranc MP. IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF[J]. Nucleic acids research, 2009; 38(suppl_1): D301-D307.

[0133] The term "antibody" is not limited to any particular method of producing the antibody. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody can be of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.

[0134] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. ( G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975; 256 (5517): 495), but it can also be obtained by using recombinant DNA technology (see, for example, US Patent 4,816,567).

[0135] As used herein, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature 1986; 321: 522 525; Reichmann et al., Nature, 1988; 332: 323 329; Presta, Curr. Op. Struct. Biol. 1992; 2: 593-596; and Clark, Immunol. Today 2000; 21: 397 402. In some cases, the antigen-binding fragment of an antibody is a diabodies, in which V H and V LThe domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 1993; 90: 6444-6448 and Poljak RJ et al., Structure 1994; 2: 1121-1123).

[0136] A fusion protein as described herein is a protein product co-expressed by two genes obtained by DNA recombination. Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art (e.g., Cold Spring Harbor Laboratory Manual of Antibody Laboratory Techniques, Chapters 5-8 and 15).

[0137] As used herein, the term "single chain fragment variable (ScFv)" refers to a single chain antibody comprising an antibody heavy chain variable region (V H ) and antibody light chain variable region (V L ) molecule. Where V L and V H The domains are paired to form monovalent molecules via linkers that enable their production as a single polypeptide chain (see, e.g., Bird et al, Science 1988; 242:423-426 and Huston et al, Proc. Natl. Acad. Sci. USA 1988; 85:5879-5883). Such scFv molecules may have the general structure: NH2-V L -Connection fragment-V H -COOH or NH2-V H -Connection fragment-V L-COOH. Suitable prior art linkers consist of repeated GGGGS (SEQ ID NO: 69) amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 (SEQ ID NO: 66) can be used, but variants thereof can also be used (Holliger et al, Proc. Natl. Acad. Sci. USA 1993; 90: 6444-6448). Other linkers that can be used in the present invention are described by Alfthan et al, Protein Eng. 1995; 8: 725-731, Choi et al, Eur. J. Immunol. 2001; 31: 94-106, Hu et al, Cancer Res. 1996; 56: 3055-3061, Kipriyanov et al, J. Mol. Biol. 1999; 293: 41-56 and Roovers et al, Cancer Immunology, Immunotherapy, 2001, 50(1): 51-59.

[0138] As used herein, the term "isolated" or "isolated" refers to something that is obtained artificially from its natural state. If a substance or component is "isolated" in nature, it may be that its natural environment has been changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and a highly pure identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.

[0139] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.

[0140] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, GS cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.

[0141] In the present invention, the term "ADCP" refers to antibody-dependent cellular phagocytosis. The Fc region of an antibody bound to a cell surface antigen binds to the Fc receptor of cells with phagocytic activity, such as macrophages, thereby mediating the phagocytosis of the antibody-bound cell by the phagocytic cell.

[0142] As used herein, the term "ADCC" refers to antibody-dependent cell-mediated cytotoxicity. The Fab segment of an antibody binds to antigenic epitopes on virus-infected cells or tumor cells, while its Fc segment binds to Fc receptors (FcRs) on the surface of killer cells (NK cells, macrophages, etc.), mediating the direct killing of target cells by these cells.

[0143] As used herein, the term "CDC" refers to complement-dependent cytotoxicity. When antibodies specifically bind to corresponding antigens on the cell membrane, they form complexes that activate the complement system. This complex, in turn, forms MACs on the target cell surface, leading to cell lysis. Complement can lyse the cells of various bacteria and other pathogens and is a crucial defense mechanism against infection by pathogens.

[0144] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Affinity of M or less (K D ) binds to the antigen.

[0145] As used herein, the term "K D " refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies bind with a dissociation equilibrium constant of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less dissociation equilibrium constant (K D ) binds to an antigen (eg, TIGIT protein). K can be determined using methods known to those skilled in the art. D , for example, using a ForteBio molecular interaction instrument.

[0146] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably. In the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0147] As used herein, the term "pharmaceutically acceptable excipient" refers to carriers and / or excipients that are pharmacologically and / or physiologically compatible with the subject and the active ingredient, and is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19 th ed. Pennsylvania: Mack Publishing Company, 1995), and include, but are not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffer; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.

[0148] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, the effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight, and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.

[0149] In the present invention, unless otherwise specified, the "first" (e.g., the first protein functional region or the first product) and "second" (e.g., the second protein functional region or the second product) are for the purpose of distinguishing references or clarifying expressions, and do not have a typical order meaning.

[0150] Advantageous Effects of the Invention

[0151] The present invention achieves any one or more of the following technical effects (1) to (8):

[0152] (1) The fusion protein of the present invention can simultaneously inhibit TIGIT and reduce TGF-β levels.

[0153] (2) The fusion protein of the present invention can bind to TIGIT very specifically and can effectively block the binding of TIGIT to CD155, specifically relieving the immune suppression of the body by TIGIT.

[0154] (3) The fusion protein of the present invention can bind to TGF-β very specifically and can very effectively block the binding of TGF-β to TGF-β receptors, specifically relieving the immune suppression of the body by TGF-β and activating the immune response.

[0155] (4) The fusion protein of the present invention has good potential for preparing anti-tumor drugs.

[0156] (5) The first protein functional domain and the second protein functional domain of the fusion protein of the present invention have a synergistic effect, which is better than using only one of the protein functional domains, for example, better than using only an anti-TIGIT antibody.

[0157] (6) The fusion protein of the present invention can effectively block the immunosuppression of immune cells induced by TIGIT and induce cells to secrete IL-2.

[0158] (7) The fusion protein of the present invention can effectively block the immunosuppression of immune cells induced by TGF-β and induce cells to secrete INF-γ.

[0159] (8) The fusion protein of the present invention overcomes the defects of easy breakage and degradation. BRIEF DESCRIPTION OF THE DRAWINGS

[0160] Figure 1: Binding activity test results of TF01, TF02, 26B12H2L2 (hG4DM), RG6058 (hG4) and antigen TIGIT-mFc.

[0161] Figure 2: Binding activity test results of TF01, TF02, TGF-βRII-mFc and TGF-β1.

[0162] Figure 3: Binding activity detection results of TF01, TF02, TGF-βRII-mFc and TGF-β2.

[0163] Figure 4: Binding activity detection results of TF01, TF02, TGF-βRII-mFc and TGF-β3.

[0164] Figure 5: Activity test results of the competition between the fusion protein of anti-TIGIT antibody and TGF-βR and TGF-βRII-His-Biotin for binding to human TGF-β1.

[0165] Figure 6: Activity test results of the competition between the fusion protein of anti-TIGIT antibody and TGF-βR and TGF-βRII-His-Biotin for binding to human TGF-β3.

[0166] Figure 7: Activity detection results of the fusion protein of anti-TIGIT antibody and TGF-βR competing with human CD155-hFc-Biotin for binding to human TIGIT-mFC.

[0167] Figure 8: Binding activity test results of anti-TIGIT antibody and TGF-βR fusion protein to TIGIT on the surface of 293T-TIGIT membrane.

[0168] Figure 9: Detection results of TF01 competing with CD155 for binding to the cell membrane surface antigen TIGIT.

[0169] Figure 10: Detection results of TF01 competing with CD112 for binding to the cell membrane surface antigen TIGIT.

[0170] Figure 11: Affinity constant detection results of TF01 and FcγRI.

[0171] Figure 12: Detection results of affinity constants between 26B12H2L2 (hG1WT) and FcγRI. Figure 13: Detection results of affinity constants between TF01 and FcγRIIIa_V158.

[0172] FIG14 shows the affinity constant test results of 26B12H2L2 (hG1WT) and FcγRIIIa_V158.

[0173] Figure 15: Affinity constant detection results of TF01 and FcγRIIIa_F158.

[0174] FIG16 : Affinity constant detection results of 26B12H2L2 (hG1WT) and FcγRIIIa_F158.

[0175] FIG17 : Affinity constant detection results of TF01 and FcγRIIa_H131.

[0176] FIG18 : Affinity constant detection results of 26B12H2L2 (hG1WT) and FcγRIIa_H131.

[0177] Figure 19: Affinity constant detection results of TF01 and FcγRIIa_R131.

[0178] FIG20 : Affinity constant detection results of 26B12H2L2 (hG1WT) and FcγRIIa_R131.

[0179] Figure 21: Affinity constant detection results of TF01 and FcγRIIb.

[0180] FIG22 : Affinity constant detection results of 26B12H2L2 (hG1WT) and FcγRIIb.

[0181] Figure 23: Affinity constant detection results of TF01 and C1q.

[0182] FIG24 : Affinity constant detection results of 26B12H2L2 (hG1WT) and C1q.

[0183] Figure 25: ADCP effect results of RG6058 (hG1WT), RG6058 (hG4WT), 26B12H2L2 (hG1WT), and TF01.

[0184] Figure 26: Evaluation results of the blocking activity of the fusion protein of anti-TIGIT antibody and TGF-βR on CD112 inhibition of IL-2 secretion in the co-culture system of Jurkat-TIGIT and THP-1 cells.

[0185] Figure 27: Evaluation results of the blocking activity of the fusion protein of anti-TIGIT antibody and TGF-βR on CD155 inhibition of IL-2 secretion in the co-culture system of Jurkat-TIGIT and THP-1 cells.

[0186] Figure 28: Results of biological activity evaluation of the fusion protein of anti-TIGIT antibody and TGF-βR in promoting IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system.

[0187] Figure 29: Evaluation results of the blocking activity of the fusion protein of anti-TIGIT antibody and TGF-βR on the IFN-γ secretion of the TGF-β1 inhibitory system during the secondary immune response of PBMC to CMV antigen.

[0188] Figure 30: Efficacy of anti-TIGIT antibody and TGF-βR fusion protein in the MDA-MB-231 xenograft tumor model in Scid Beige mice. Results are presented as mean ± standard error and analyzed by two-way ANOVA followed by Bonferroni test. Compared with the isotype control group: *p < 0.05, **p < 0.01, ***p < 0.001.

[0189] Figure 31: Effects of anti-TIGIT antibody and TGF-βR fusion protein on body weight in Scid Beige mouse MDA-MB-231 transplanted tumor model.

[0190] Figure 32: Bioactivity evaluation results of antibodies TF01A, TF01G, TF01T, TF01t31 and TF01t37 in promoting IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system.

[0191] Figure 33: Evaluation results of the neutralization effect of anti-TIGIT antibody and TGF-βR fusion protein on TGF-β1 inhibiting IL-4-induced TF-1 proliferation.

[0192] Figure 34: Evaluation results of the neutralization effect of anti-TIGIT antibody and TGF-βR fusion protein on TGF-β3 inhibition of IL-4-induced TF-1 proliferation.

[0193] Figure 35: Reporter gene experiment evaluation results of anti-TIGIT antibody and TGF-βR fusion protein blocking the interaction between TGF-β1 and TGF-βR.

[0194] Figure 36: Reporter gene assay results showing that the fusion protein of anti-TIGIT antibody and TGF-βR blocks the interaction between TGF-β3 and TGF-βR.

[0195] Figure 37: Results of reporter gene experiments evaluating the blocking effect of anti-TIGIT antibody and TGF-βR fusion protein on the interaction between TIGIT and PVR.

[0196] Figure 38: Molecular weight detection results of the fusion protein TF01 of anti-TIGIT antibody and TGF-βR.

[0197] Figure 39: Molecular weight detection results of the fusion protein TF01A of anti-TIGIT antibody and TGF-βR.

[0198] Figure 40: Molecular weight detection results of the fusion protein TF01G of anti-TIGIT antibody and TGF-βR.

[0199] Figure 41: Molecular weight detection results of the fusion protein TF01T of anti-TIGIT antibody and TGF-βR.

[0200] Figure 42: Molecular weight detection results of the fusion protein TF01t31 of anti-TIGIT antibody and TGF-βR.

[0201] Figure 43: Molecular weight detection results of the fusion protein TF01t37 of anti-TIGIT antibody and TGF-βR.

[0202] Figure 44 shows the results of SEC-HPLC analysis of the fusion protein TF01 of anti-TIGIT antibody and TGF-βR.

[0203] Figure 45: SEC-HPLC analysis results of the fusion protein TF01T of anti-TIGIT antibody and TGF-βR.

[0204] Figure 46: Graph showing the binding activity of the fusion protein of anti-TIGIT antibody and TGF-βR to TGF-β1.

[0205] Figure 47: Mixed lymphocyte reaction to detect the biological activity of the fusion protein of anti-TIGIT antibody and TGF-βR in promoting IFN-γ secretion.

[0206] Deposited biological materials:

[0207] The hybridoma cell line LT019 (TIGIT-26B12) was deposited in the China Center for Type Culture Collection (CCTCC) on October 23, 2020, with the deposit number CCTCC NO: C2020208, and the deposit address is Wuhan University, Wuhan, China, Postal Code: 430072.

[0208] The partial sequences involved in the present invention are as follows:

[0209] 1. Amino acid sequence of 26B12VH

[0210] 2. Nucleic acid sequence of 26B12VH

[0211] 3.HCDR1:

[0212] 4.HCDR2:

[0213] 5.HCDR3:

[0214] Amino acid sequence of 6.26B12VL

[0215] 7. Nucleic acid sequence of 26B12VL

[0216] 8.LCDR1:

[0217] 9.LCDR2:

[0218] 10.LCDR3:

[0219] 11. Amino acid sequence of 26B12H1VH

[0220] 12. Nucleic acid sequence of 26B12H1VH

[0221] 13. Amino acid sequence of 26B12H2VH

[0222] 14. Nucleic acid sequence of 26B12H2VH

[0223] 15. Amino acid sequence of 26B12H3VH

[0224] 16. Nucleic acid sequence of 26B12H3VH

[0225] 17. Amino acid sequence of 26B12H4VH

[0226] 18. Nucleic acid sequence of 26B12H4VH

[0227] 19. Amino acid sequence of 26B12L1VL

[0228] 20. Nucleic acid sequence of 26B12L1VL

[0229] 21. Amino acid sequence of 26B12L2VL

[0230] 22. Nucleic acid sequence of 26B12L2VL

[0231] 23. Amino acid sequence of 26B12L3VL

[0232] 24. Nucleic acid sequence of 26B12L3VL

[0233] 25. Amino acid sequence of 26B12L4VL

[0234] 26. Nucleic acid sequence of 26B12L4VL

[0235] 27. Amino acid sequence of 26B12H2L2 (hG4DM) heavy chain

[0236] 28. Nucleic acid sequence of 26B12H2L2 (hG4DM) heavy chain

[0237] 29. Amino acid sequence of the light chain of 26B12H2L2 (hG4DM)

[0238] 30. Nucleic acid sequence of 26B12H2L2 (hG4DM) light chain

[0239] 31. 26B12H2L2 (hG1DM) heavy chain amino acid sequence

[0240] 32. 26B12H2L2 (hG1DM) heavy chain nucleic acid sequence

[0241] 33. Amino acid sequence of TGF-βRII extracellular domain fragment (truncated):

[0242] 34. Amino acid sequence of TGF-βRI: (The underlined portion is the sequence of the extracellular region)

[0243] 35.Amino acid sequence of the extracellular region of TGF-βRI:

[0244] 36. Amino acid sequence of TGF-βRⅡ: (The underlined portion is the extracellular region sequence)

[0245] 37.Amino acid sequence of the extracellular region of TGF-βRⅡ:

[0246] 38. Amino acid sequence of TGF-βRⅢ: (The underlined portion is the extracellular domain sequence)

[0247] 39.Amino acid sequence of the extracellular region of TGF-βRⅢ:

[0248] 40.Amino acid sequence of Tiragolumab heavy chain:

[0249] 41.Amino acid sequence of the light chain of Tiragolumab:

[0250] 42.Amino acid sequence of the heavy chain variable region of RG6058 (hG4):

[0251] 43.Amino acid sequence of the light chain variable region of RG6058 (hG4):

[0252] 44.Amino acid sequence of the connecting fragment:

[0253] 45. Anti-HEL & TGFβ antibody heavy chain amino acid sequence

[0254] 46.Anti-HEL & TGFβ antibody light chain amino acid sequence

[0255] 47. Heavy chain amino acid sequence of RG6058 (G1DM)

[0256] 48. Light chain amino acid sequence of RG6058 (G1DM)

[0257] 49. Amino acid sequence of TGF-βRII extracellular domain variant of TF01A:

[0258] 50. Amino acid sequence of TGF-βRII extracellular domain variant of TF01G:

[0259] 51. Amino acid sequence of TGF-βRII extracellular domain variant of TF01T:

[0260] 52. Amino acid sequence of the TGF-βRII extracellular domain variant of the TF01t31 antibody:

[0261] 53. Amino acid sequence of the TGF-βRII extracellular domain variant of the TF01t37 antibody:

[0262] 54. Variants of the TGF-βRII extracellular domain fragment

[0263] 55. Variants of the extracellular domain of TGF-βRII

[0264] 56. Variants of the TGF-βRII extracellular domain fragment

[0265] 57. Variants of the TGF-βRII extracellular domain fragment

[0266] 58. Variants of the TGF-βRII extracellular domain fragment

[0267] 59. Deleted fragments in the extracellular domain of TGF-βRII

[0268] 60. Deleted fragments in the extracellular domain of TGF-βRII

[0269] 61. Deleted fragments in the extracellular domain of TGF-βRII

[0270] 62. Deleted fragments in the extracellular domain of TGF-βRII

[0271] 63. Deleted fragments in the extracellular domain of TGF-βRII

[0272] 64. Deleted fragments in the extracellular domain of TGF-βRII

[0273] 65. Deleted fragments in the extracellular domain of TGF-βRII

[0274] 66. Connecting Fragments

[0275] 67.hIgG4WT heavy chain constant region amino acid sequence

[0276] 68.hIgG1WT heavy chain constant region amino acid sequence

[0277] 69. Connecting Fragments

[0278] 70. Connecting fragments

[0279] 71.B12-hG1 heavy chain amino acid sequence

[0280] 72.B12-hG1 light chain amino acid sequence DETAILED DESCRIPTION

[0281] The embodiments of the present invention will be described in detail below with reference to the examples, but it will be understood by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0282] BALB / c mice were purchased from Guangdong Medical Laboratory Animal Center.

[0283] C57 mice were purchased from the Experimental Animal Center of Guangzhou University of Chinese Medicine.

[0284] MDA-MB-231 cells, U87-MG cells, and TF-1 cells were purchased from ATCC.

[0285] A549 cells were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0286] The heavy chain amino acid sequence and light chain amino acid sequence of the positive control antibody Tiragolumab are derived from the antibody described in WHO. Proposed INN: List 117. WHO Drug Information, 31(2): p104, 2017, and the sequences are identical to SEQ ID NOs: 40-41, respectively.

[0287] Tiragolumab and RG6058 (hG1WT) described in the present invention are the same antibody.

[0288] The positive control antibody RG6058 (hG4) has a sequence derived from the antibody described in patent publication CN108290946A, and its heavy chain variable region amino acid sequence and light chain variable region amino acid sequence are identical to SEQ ID NOs: 42-43, respectively.

[0289] The positive control antibody RG6058 (hG1DM) was prepared in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd., batch number 20180816. Its heavy chain amino acid sequence is shown in SEQ ID NOs: 47, and its light chain amino acid sequence is shown in SEQ ID NOs: 48.

[0290] In the following examples of the present invention, the isotype control antibody used is human anti-hen egg lysozyme IgG (anti-HEL, i.e., human IgG, abbreviated as hIgG), the variable region sequence of which is derived from the Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies published by Acierno et al. (Acierno et al. J Mol Biol. 2007; 374(1): 130-46.). The hIgG1DM and hIgG4WT used in the examples are isotype control antibodies of anti-HEL with hG1DM and hG4WT constant region sequences, which were prepared in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd.

[0291] The anti-HEL & TGFβ antibody is constructed by fusion of the heavy chain C-terminus of the human hG4DM, k subtype anti-HEL antibody with the TGFβRII protein. It was produced in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd. The amino acid sequence of its heavy chain is shown in SEQ ID NOs:45, and the amino acid sequence of its light chain is shown in SEQ ID NOs:46.

[0292] TIGIT-mFc protein (batch number 20171110), TGF-βRII-mFc (batch number 20200528), CD155-hFc-Biotin (batch number 20170721), CD155-mFc (batch number 20190726), and CD112-mFc (batch number 20190726) are all produced by Zhongshan Kangfang Biopharmaceutical Co., Ltd. according to known sequences, where mFc represents the Fc protein fragment of mouse IgG; hFc represents the Fc protein fragment of human IgG.

[0293] TGF-β1 protein was purchased from Sino Biologcal Inc., catalog number: LC13DE3108.

[0294] TGF-β2 protein was purchased from Peprotech, catalog number: 0420345E0620.

[0295] TGF-β3 protein was purchased from Peprotech, catalog number: 0713410A0219.

[0296] In the following examples of the present invention, the 293T-TIGIT cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The 293T-TIGIT cell line was prepared by infecting HEK293T cells (Wuhan University) with viruses. The virus preparation used was 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was plenti6.3 / V5-TIGITFL-BSD (TIGIT, Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen, product number: K531520).

[0297] In the following examples of the present invention, the CHO-K1-TIGIT cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The CHO-K1-TIGIT cell line was prepared by virus infection of CHO-K1 cells (Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences). The virus preparation used was 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was plenti6.3 / V5-TIGITFL-BSD (TIGIT, Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen, product number: K531520).

[0298] In the following examples of the present invention, the Jurkat-TIGIT cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The Jurkat-TIGIT cell line was prepared by virus infection of Jurkat cells (Cell Center, Chinese Academy of Sciences). The virus preparation used was 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was plenti6.3 / V5-TIGITFL-BSD (TIGIT, Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen, product number: K531520).

[0299] In the following examples of the present invention, the HT1080-aCD3scFv cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The HT1080-aCD3scFv cell line was prepared by virus infection of HT-1080 cells (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences). The virus preparation used was 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was pCDH-aCD3scFv-Puro (wherein the aCD3scFv sequence was derived from the anti-human CD3 Mus musculus OKT3 hybridoma antibody; the vector pCDH-CMV-MCS-EF1-Puro was purchased from Youbao Bio, product number: VT1480).

[0300] In the following examples of the present invention, the 293T-TGFβR2-Luc cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The 293T-TGFβR2-Luc cell line was prepared by virus infection of HEK293T cells (Wuhan University). The virus was prepared using 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vectors used were pCDH-hTGFBR2FL-puro and pCDH-Smad3 / 4-Luc2P-Hygro (hTGFBR2FL Genebank ID: NP_003233.4; vector pCDH-CMV-MCS-EF1-Puro, purchased from Youbao Bio, product number: VT1480; pCDH-Smad3 / 4-Luc2P-Hygro was constructed by Kangfang).

[0301] In the following examples of the present invention, the Jurkat-TIGIT-NFAT-Luc cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The Jurkat-TIGIT-NFAT-Luc cell line was prepared by virus infection of Jurkat cells (Cell Center, Chinese Academy of Sciences). The virus was prepared using 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vectors used were plenti6.3 / V5-TIGITFL-BSD and pCDH-NFAT-hygro (TIGIT, Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen, product number: K531520; pCDH-NFAT-hygro was constructed by Kangfang).

[0302] In the following examples of the present invention, the CHO-aAPC-PDL1-PVR cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. The CHO-aAPC-PDL1-PVR cell line was prepared by virus infection of PD-L1 aAPC / CHO-K1 cells (purchased from Promega), and the virus preparation used was 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini LJ Virol. 1998. 72(11): 8463-8471. The lentiviral expression vector used was pCDH-PVRFL-Puro (PVRFL Genebank ID: NP_006496.4; vector pCDH-CMV-MCS-EF1-Puro, purchased from Youbao Bio, product number: VT1480).

[0303] Example 1: Preparation of anti-TIGIT antibodies

[0304] 1. Preparation of Hybridoma Cell Line LT019

[0305] The antigen used to prepare anti-TIGIT antibodies is human TIGIT-mFc (TIGIT is Genbank ID: NP_776160.2). The spleen cells of immunized mice were fused with mouse myeloma cells to make hybridoma cells. Using human TIGIT-hFc as the antigen, the hybridoma cells were screened by indirect ELISA to obtain hybridoma cells that can secrete antibodies that specifically bind to TIGIT. The hybridoma cells obtained by screening were subjected to the limiting dilution method to obtain a stable hybridoma cell line. The above hybridoma cell line was named hybridoma cell line LT019, and the monoclonal antibody it secreted was named 26B12.

[0306] The hybridoma cell line LT019 (also known as TIGIT-26B12) was deposited in the China Center for Type Culture Collection (CCTCC) on October 23, 2020, with the deposit number CCTCC NO: C2020208, and the deposit address is Wuhan University, Wuhan, China, Postal Code: 430072.

[0307] 2. Preparation of Anti-TIGIT Antibody 26B12

[0308] The LT019 cell line prepared above was cultured in CD medium (Chemical Defined Medium, containing 1% penicillin-streptomycin) at 5% CO₂ and 37°C. After 7 days, the cell culture supernatant was collected, centrifuged, vacuum filtered through a microporous filter, and purified using a HiTrap protein A HP column to produce the antibody 26B12.

[0309] Example 2: Sequence Analysis of Anti-TIGIT Antibody 26B12

[0310] mRNA was extracted from the LT019 cell line cultured in Example 1 according to the method of the Cultured Cell Bacterial Total RNA Extraction Kit (Tiangen, Catalog No. DP430).

[0311] According to Invitrogen III First-Strand Synthesis System for RT-PCR Kit Instructions: Synthesize cDNA and perform PCR amplification.

[0312] The PCR amplified products were directly subjected to TA cloning. The specific operation was carried out according to the instructions of the pEASY-T1 Cloning Kit (Transgen CT101).

[0313] The TA cloned products were directly sequenced, and the sequencing results were as follows:

[0314] The nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 2, and the fragment is 363 bp long.

[0315] The amino acid sequence encoded by the gene is shown in SEQ ID NO: 1, and has a length of 121 amino acids.

[0316] The sequence of the heavy chain HCDR1 is shown in SEQ ID NO: 3, the sequence of HCDR2 is shown in SEQ ID NO: 4, and the sequence of HCDR3 is shown in SEQ ID NO: 5.

[0317] The nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 7, with a length of 321 bp.

[0318] The amino acid sequence encoded by the gene is shown in SEQ ID NO: 6, and has a length of 107 amino acids.

[0319] The sequence of the light chain LCDR1 is shown in SEQ ID NO: 8, the sequence of LCDR2 is shown in SEQ ID NO: 9, and the sequence of LCDR3 is shown in SEQ ID NO: 10.

[0320] Example 3: Design and preparation of humanized antibodies and mutant antibodies against human TIGIT

[0321] 1. Light and heavy chain design of humanized anti-human TIGIT antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4

[0322] Based on the three-dimensional crystal structure of human TIGIT protein and the sequence of antibody 26B12 obtained in Example 2, the variable region sequences of antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4 were designed (antibody constant region sequences, from the NCBI database, the heavy chain constant region all used Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region was Ig kappa chain C region, ACCESSION: P01834).

[0323] The designed variable region sequences are shown in Table 1 below.

[0324] Table 1: Variable region sequences of humanized antibodies against human TIGIT

[0325] The above eight antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4, the nucleic acid sequence length of the heavy chain variable region is 363 bp, the length of the amino acid sequence encoded therein is 121 aa; the nucleic acid sequence length of the light chain variable region is 321 bp, the length of the amino acid sequence encoded therein is 107 aa.

[0326] And the above 8 antibodies have the same HCDR1-HCDR3 and LCDR1-LCDR3, as follows:

[0327] The sequence of HCDR1 is shown in SEQ ID NO: 3, the sequence of HCDR2 is shown in SEQ ID NO: 4, and the sequence of HCDR3 is shown in SEQ ID NO: 5;

[0328] The sequence of LCDR1 is shown in SEQ ID NO: 8, the sequence of LCDR2 is shown in SEQ ID NO: 9, and the sequence of LCDR3 is shown in SEQ ID NO: 10.

[0329] 2. Preparation of Humanized Antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4

[0330] The heavy chain constant region all used the Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region all used the Ig kappa chain C region, ACCESSION: P01834.

[0331] The heavy chain cDNA and light chain cDNA of 26B12H1L1, the heavy chain cDNA and light chain cDNA of 26B12H4L1, the heavy chain cDNA and light chain cDNA of 26B12H2L2, the heavy chain cDNA and light chain cDNA of 26B12H3L2, the heavy chain cDNA and light chain cDNA of 26B12H2L3, the heavy chain cDNA and light chain cDNA of 26B12H3L3, the heavy chain cDNA and light chain cDNA of 26B12H1L4, the heavy chain cDNA and light chain cDNA of 26B12H2L4, and the heavy chain cDNA and light chain cDNA of 26B12H4L4 were cloned into pUC57simple vector (provided by GenScript) to obtain the following:

[0332] pUC57simple-26B12H1, pUC57simple-26B12L1;

[0333] pUC57simple-26B12H4, pUC57simple-26B12L1;

[0334] pUC57simple-26B12H2, pUC57simple-26B12L2;

[0335] pUC57simple-26B12H3, pUC57simple-26B12L2;

[0336] pUC57simple-26B12H2, pUC57simple-26B12L3;

[0337] pUC57simple-26B12H3, pUC57simple-26B12L3;

[0338] pUC57simple-26B12H1, pUC57simple-26B12L4; and

[0339] pUC57simple-26B12H4, pUC57simple-26B12L4.

[0340] Referring to the standard techniques described in the Molecular Cloning Laboratory Manual (Second Edition), the full-length heavy and light chain genes synthesized by EcoRI & HindIII digestion were subcloned into the expression vector pcDNA3.1 by restriction enzyme digestion (EcoRI & HindIII) to obtain expression plasmids pcDNA3.1-26B12H1, pcDNA3.1-26B12L1, pcDNA3.1-26B12H4, pcDNA3.1-126B12H2, pcDNA3.1-26B12L2, pcDNA3.1-26B12H3, pcDNA3.1-26B12L3 and pcDNA3.1-26B12L4, and the heavy / light chain genes of the recombinant expression plasmids were further sequenced and analyzed. Subsequently, the recombinant plasmids containing the corresponding light and heavy chain gene combinations (pcDNA3.1-26B12H1 / pcDNA3.1-26B12L1, pcDNA3.1-26B12H4 / pcDNA3.1-26B12L1, pcDNA3.1-26B12H2 / pcDNA3.1-26B12L2, pcDNA3.1-26B12H3 / pcDNA3.1-26B12L2 , pcDNA3.1-26B12H2 / pcDNA3.1-26B12L3, pcDNA3.1-26B12H3 / pcDNA3.1-26B12L3, pcDNA3.1-26B12H1 / pcDNA3.1-26B12L4, and pcDNA3.1-26B12H4 / pcDNA3.1-26B12L4) were co-transfected into 293F cells, and the culture medium was collected for purification. After sequencing verification, endotoxin-free expression plasmids were prepared and transiently transfected into HEK293 cells for antibody expression. After 7 days of culture, the cell culture medium was collected and affinity purified using a Protein A column to obtain the humanized antibody.

[0341] The humanized antibody 26B12H2L2 is also referred to as 26B12H2L2 (hG1WT) in the present invention.

[0342] 3. Design of humanized antibodies 26B12H2L2(hG1DM) and 26B12H2L2(hG4DM)

[0343] Based on 26B12H2L2, the present inventors introduced a leucine-to-alanine point mutation (L234A) at position 234 (according to the EU numbering system, the same below) and a leucine-to-alanine point mutation (L235A) at position 235 of the heavy chain constant region to obtain a humanized antibody with constant region mutations, 26B12H2L2(hG1DM). The amino acid sequence of the heavy chain of 26B12H2(hG1DM) is shown in SEQ ID NO:31; the amino acid sequence of the light chain is shown in SEQ ID NO:29.

[0344] Based on 26B12H2L2, the inventors retained the variable region of the antibody and used the Ig gamma-4 chain C region as the heavy chain constant region. They also introduced a point mutation from phenylalanine to alanine (F234A) at position 234 of the heavy chain constant region, and a point mutation from leucine to alanine (L235A) at position 235 of the heavy chain constant region, thereby obtaining a humanized antibody with constant region mutations, 26B12H2L2 (hG4DM). The amino acid sequence of the heavy chain of 26B12H2 (hG4DM) is shown in SEQ ID NO: 27; the amino acid sequence of the light chain of 26B12H2L2 (hG4DM) is shown in SEQ ID NO: 29.

[0345] The preparation of humanized antibodies 26B12H2L2 (hG1DM) and 26B12H2L2 (hG4DM) can refer to the method in step 2 above.

[0346] Example 4: Sequence design and preparation of anti-TIGIT antibody and TGF-βR fusion protein

[0347] 1. Sequence Design

[0348] The composition of the fusion protein of the anti-TIGIT antibody and TGF-βR in the present invention is shown in Table 2 below.

[0349] Table 2: Composition of heavy and light chains of anti-TIGIT antibody and TGF-βR fusion proteins

[0350] The TGF-β receptor portion has two peptide chains, each of which is connected to the C-terminus of the heavy chain of the IgG portion through a connecting fragment.

[0351] 2. Antibody Expression and Purification

[0352] The heavy chain cDNA sequences and light chain cDNA sequences of TF01 and TF02 were cloned into the pUC57simple vector (provided by GenScript) to obtain pUC57simple-TF01H, pUC57simple-TF02H, pUC57simple-TF02L, and pUC57simple-TF02L plasmids, respectively.

[0353] Plasmids pUC57simple-TF01H / pUC57simple TF01L and pUC57simple-TF02H / pUC57simple TF02L were digested with HindIII and EcoRI, respectively. The heavy and light chains were recovered by electrophoresis and subcloned into the pcDNA3.1 vector. The recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the culture medium was centrifuged at high speed, the supernatant was concentrated, and then loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step with Elution Buffer, and the target sample was recovered and exchanged with PBS. This produced the anti-TIGIT antibody and TGF-βR fusion proteins TF01 and TF02.

[0354] Example 5: Sequence design and preparation of anti-TIGIT antibody and TGF-βR fusion protein (mutant)

[0355] Point mutations were performed on the TGF-βRII extracellular domain fragment in the anti-TIGIT antibody of the present invention and the TGF-βR fusion protein TF01, and the serine at position 8 of the TGF-βRII extracellular domain fragment (SEQ ID NO: 33) was mutated to alanine, glycine or threonine, respectively. The resulting new antibodies were named TF01A, TF01G and TF01T, respectively. Their preparation refers to Example 4.

[0356] Table 3: Composition of heavy and light chains of fusion proteins (mutants) of anti-TIGIT antibodies and TGF-βR

[0357] Example 6: Sequence design and preparation of anti-TIGIT antibody and TGF-βR fusion protein (truncated form)

[0358] The TGF-βRII extracellular region fragment in the fusion protein TF01 of the anti-TIGIT antibody and TGF-βR in the present invention was partially truncated, and the sequence IPPHVQKS was deleted. The resulting fusion protein was named TF01t31; the sequence IPPHVQKSVNNDMI was deleted, and the resulting fusion protein was named TF01t37. Its preparation refers to Example 4.

[0359] Table 4: Composition of heavy and light chains of anti-TIGIT antibody and TGF-βR fusion protein (truncated form)

[0360] Example 7: ELISA method to determine the binding activity of TF01, TF02 and antigen or TGF-β

[0361] 1. Indirect ELISA method was used to determine the binding activity of TF01, TF02, 26B12H2L2 (hG4DM), RG6058 (hG4) with the antigen TIGIT-mFc

[0362] The specific method is as follows:

[0363] ELISA plates were coated with 2 μg / mL goat anti-mouse IgG Fc (Jackson, Cat. No. 115-005-071) and incubated overnight at 4°C. The plates were then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plates were washed three times with PBST. 1 μg / mL TIGIT-mFc was added and incubated at 37°C for 30 minutes. After washing three times with PBST, the antibodies were serially diluted in PBST (see Table 5 for the antibody dilution series). The plates were incubated at 37°C for 30 minutes and washed three times with PBST. After washing, HRP-conjugated goat anti-human IgG (H+L) (Jackson, Cat. No. 109-035-098) secondary antibody was added at a 1:5000 dilution and incubated at 37°C for 30 minutes. After incubation, the plate was washed four times with PBST. TMB (Neogen, 308177) was then added and color was developed for 5 minutes in the dark. The color reaction was terminated by adding stop solution. The plate was immediately placed in a microplate reader and the OD values ​​of each well were read at 450 nm. Data were analyzed using SoftMax Pro 6.2.1 software.

[0364] The test results are shown in Table 5 and Figure 1.

[0365] Table 5: ELISA detection of the binding of TF01, TF02, 26B12H2L2 (hG4DM), RG6058 (hG4) to TIGIT-mFc

[0366] As shown in the figure, TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) can effectively bind to the antigen TIGIT-mFc in a dose-dependent manner. The EC values ​​of each dose are 50The values ​​are shown in Table 3. The binding efficiency EC of TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) (as a control) was obtained by quantitative absorbance analysis of the bound antibodies and curve simulation calculation. 50 They are 0.067nM, 0.091nM, 0.046nM and 0.055nM respectively.

[0367] The above experimental results show that TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) have the activity of effectively binding to TIGIT-mFc.

[0368] 2. Indirect ELISA method was used to determine the binding activity of TF01, TF02, TGF-βRII-mFc with TGF-β1, TGF-β2, and TGF-β3

[0369] The specific method is as follows:

[0370] ELISA plates were coated with TGF-β1, TGF-β2, and TGF-β3 at 1 μg / mL, 2 μg / mL, and 1 μg / mL, respectively, and incubated overnight at 4°C. The antigen-coated plates were then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plates were washed three times with PBST, and serially diluted antibodies and TGF-βRII-mFc in PBST were added. The plates were then incubated with the test antibodies and TGF-βRII-mFc at 37°C for 30 minutes. After incubation, the plates were washed three times with PBST. After washing, add HRP-conjugated goat anti-human IgG (H+L) (Jackson, Catalog No. 109-035-098) and HRP-conjugated goat anti-mouse IgG Fc (Jackson, Catalog No. 115-035-071) secondary antibodies at a dilution of 1:5000 and incubate at 37°C for 30 minutes. After incubation, wash the plate four times with PBST and add TMB (Neogen, 308177) for 5 minutes in the dark. The color reaction is terminated by adding stop solution. Immediately place the plate in a microplate reader and read the OD value of each well at a wavelength of 450 nm. Data were analyzed using SoftMax Pro 6.2.1 software.

[0371] The test results are shown in Table 6, Table 7, Table 8 and Figures 2, 3 and 4.

[0372] Table 6: ELISA detection of the binding of TF01, TF02, TGF-βRII-mFc and TGF-β1

[0373] Table 7: ELISA detection of the binding of TF01, TF02, TGF-βRII-mFc and TGF-β2

[0374] Table 8: ELISA detection of the binding of TF01, TF02, TGF-βRII-mFc and TGF-β3

[0375] The binding efficiency EC of TF01 with TGF-β1, TGF-β2 and TGF-β3 was obtained by quantitative analysis of the absorbance of the bound antibodies and curve simulation calculation. 50 The binding efficiency of TF02 to TGF-β1, TGF-β2 and TGF-β3 were 0.207nM, 0.477nM and 0.215nM respectively. 50 The binding efficiency EC of TGF-βR2-mFc (as a positive control) to TGF-β1, TGF-β2, and TGF-β3 were 0.224nM, 0.594nM, and 0.234nM, respectively. 50 They are 0.356nM, 1.029nM and 0.402nM respectively.

[0376] The results showed that TF01 and TF02 had effective binding activity to TGF-β1, TGF-β2, and TGF-β3 in a dose-dependent manner. The results also showed that TF01, TF02, and TGF-βRII-mFc all effectively bound to TGF-β1, TGF-β2, and TGF-β3, respectively, and that TF01 and TF02 had stronger binding abilities to TGF-β1, TGF-β2, and TGF-β3 than TGF-βRII-mFc.

[0377] Example 8: Competitive ELISA method to determine the competitive binding activity of TF01, TF02 and TGF-βRII-His-Biotin to human TGF-β1 and TGF-β3

[0378] Experimental Procedure: ELISA plates were coated with TGF-β1 and TGF-β3 at 2 μg / mL each and incubated overnight at 4°C. Following incubation, the coated plates were rinsed once with PBST and then blocked with 1% BSA in PBS for 2 hours. After blocking, the plates were washed three times with PBST. Antibodies and TGF-βRII-mFc were added to the plates in serial dilutions of PBST. For TGF-β1, plates were incubated at room temperature for 60 minutes, washed three times with PBST, and then 0.01 μg / mL TGF-βRII-His-Biotin was added and incubated at room temperature for 10 minutes. For TGF-β3, plates were incubated at 37°C for 30 minutes, washed three times with PBST, and then 0.01 μg / mL TGF-βRII-His-Biotin was added and incubated at 37°C for 30 minutes. After incubation, the plates were washed three times with PBST. After washing, add SA-HRP working solution diluted 1:4000 and incubate at 37°C for 30 minutes. After incubation, wash the plate four times with PBST and add TMB (Neogen, 308177) for 4 minutes in the dark. The color reaction is terminated by adding stop solution. Immediately place the plate in a microplate reader and read the OD value of each well at 450 nm. Data were analyzed using SoftMax Pro 6.2.1 software.

[0379] The results of the competition between the antibody and TGF-βRII-His-Biotin for binding to TGF-β1 and TGF-β3 are shown in Tables 9 and 10 and Figures 5 and 6. The EC values ​​of the antibody and TGF-βRII-His-Biotin for binding to TGF-β1 and TGF-β3 were calculated by curve fitting with the antibody concentration as the abscissa and the absorbance value as the ordinate. 50 The results are shown in Tables 9 and 10 below.

[0380] Table 9: Activity test results of TF01, TF02 and TGF-βRII-His-Biotin competing for binding to TGF-β1

[0381] Table 10: Activity test results of TF01, TF02 and TGF-βRII-His-Biotin competing for binding to TGF-β3

[0382] By quantitatively analyzing the absorbance of the bound antibodies, the binding efficiency EC of TF01, TF02, TGF-βRII-mFc and TGF-βRII-His-Biotin for competitive binding to TGF-β1 was obtained. 50The binding efficiencies of TF01, TF02, TGF-βRII-mFc and TGF-βRII-His-Biotin in competing for TGF-β3 were 5.579nM, 7.469nM and 6.475nM, respectively. 50 They are 3.569nM, 3.879nM and 2.808nM respectively.

[0383] The results showed that TF01 and TF02 effectively bound to TGF-β1 and TGF-β3 in a dose-dependent manner. Furthermore, TF01's ability to bind to TGF-β1 was stronger than that of TGF-βRII-His-Biotin. TF01's ability to compete with TGF-βRII-His-Biotin for TGF-β1 was stronger than that of TGF-βRII-mFc.

[0384] Example 9: Competitive ELISA method to determine the activity of TF01, TF02 and CD155-hFc-Biotin in binding to human TIGIT-mFc

[0385] After coating the ELISA plate with human TIGIT-mFc (TIGIT Genbank ID: NP_776160.2) at 2 μg / mL, incubate at 4°C overnight. After incubation, block the ELISA plate with 1% BSA in PBS at 37°C for 2 hours. Wash the plate three times and pat dry after blocking. On the dilution plate, dilute the antibody to 7 concentrations at a 1:3 dilution ratio with a starting concentration of 20.18nM (final concentration of 10.09nM), and set up a blank control. Then add an equal volume of 4μg / mL (final concentration of 2μg / mL) human CD155-hFc-Biotin solution, mix well, and incubate at room temperature for 20 minutes. The reaction mixture is then added to the coated ELISA plate and incubated at 37°C for 30 minutes. After incubation, wash the plate three times with PBST and pat dry. Add SA-HRP (KPL, 14-30-00) working solution and incubate at 37°C for 30 minutes. After incubation, wash the plate four times and pat dry. Add TMB (Neogen, 308177) and develop the color in the dark for 5 minutes. Stop the color reaction by adding stop solution. Immediately place the plate in a microplate reader and read the OD value of each well at 450 nm. Analyze the data using SoftMax Pro 6.2.1 software.

[0386] The test results are shown in Figure 7. The OD values ​​of each dose are shown in Table 9. The EC of the binding was obtained by quantitatively analyzing the absorbance intensity of the bound antibody and simulating the binding efficiency of the antibody. 50 (Table 11).

[0387] Table 11: Activity test results of TF01, TF02, 26B12H2L2 (hG4DM), RG6058 (hG4) competing with CD155-hFc-Biotin for binding to TIGIT-mFc

[0388] TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) (as a control) blocked the binding of TIGIT-mFc to its ligand CD155-hFc-Biotin EC 50 They are 1.463nM, 1.963nM, 1.423nM and 1.675nM respectively.

[0389] The results showed that TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) (as a control) could effectively block the binding of the antigen human CD155-hFc-Biotin and its receptor human TIGIT-mFc, and the blocking efficiency was dose-dependent. TF01 had a stronger ability to block the binding of TIGIT-mFc and its ligand CD155-hFc-Biotin than the control antibody RG6058 (hG4).

[0390] Example 10: FACS detection of the binding activity of TF01 to TIGIT on the surface of 293T-TIGIT membrane

[0391] 293T-TIGIT cells were collected during the logarithmic growth phase and counted at 3x10 5 The cells were transferred to a clear conical-bottom 96-well plate, 1% PBSA was added, the cells were centrifuged at 350 g for 5 min, and the supernatant was removed. 100 μL of antibodies diluted in 1% PBSA were added (final concentrations were 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.041 nM, 0.0041 nM, and 0.00041 nM, respectively), mixed gently, and incubated on ice for 1 h. 1% PBSA was added, the cells were centrifuged at 350 g for 5 min, and the supernatant was removed. 350-fold diluted FITC-labeled goat anti-human IgG secondary antibody (Jackson, Cat. No. 109-095-098) was added, the cells were resuspended and mixed, and the cells were incubated on ice in the dark for 0.5 h. 1% PBSA was added, the cells were centrifuged at 350 g for 5 min, and the supernatant was removed. The cell pellet was resuspended in 400 μL PBSA and transferred to a flow cytometry tube for FACS. Calibur detection.

[0392] The experimental results are shown in Table 12 and Figure 8. Both TF01 and RG6058 (hG4) (control antibody) can specifically bind to TIGIT on the surface of 293T-TIGIT membrane.

[0393] Table 12: FACS detection of the binding activity of TF01 and RG6058 (hG4) to TIGIT on the surface of 293T-TIGIT cells

[0394] Under the same experimental conditions, the EC binding of TF01 and RG6058 (hG4) to 293T-TIGIT cells 50 1.540nM and 1.612nM respectively.

[0395] The results showed that TF01 has the activity of effectively binding to TIGIT on the surface of 293T-TIGIT membrane in a dose-dependent manner, and its binding ability is stronger than that of the control antibody RG6058 (hG4).

[0396] Example 11: Competitive flow cytometry assay to determine whether TF01 competes with CD155 or CD112 for binding to the cell membrane surface antigen TIGIT

[0397] 293T-TIGIT cells were routinely digested and 3x10 cells were used for each sample. 5 cells / well, centrifuged and washed; added the corresponding gradient dilution of antibodies, 100 μL per well, incubated on ice for 30 minutes; added 100 μL CD155 / CD112-mFc (Kongfang Biopharmaceuticals, batch number: 20190726 / batch number: 20190726) to each well, mixed to a final concentration of 10 nM / 30 nM, and incubated on ice for 1 hour; added 1% PBSA, centrifuged at 350 g for 5 minutes, and removed the supernatant; added 100 μL of 1:300 diluted APC Goat anti-mouse IgG antibody (Biolegend, catalog number: 405308) to each well, and added 100 μL of 1% PBSA to the blank sample, mixed and incubated on ice in the dark for 30 minutes; centrifuged and washed to resuspend, transferred to a flow cytometry loading tube, and tested on the machine.

[0398] The results are shown in Figures 9 and 10. 50 The values ​​are shown in Table 13. The competitive binding EC of TF01 was calculated by fluorescence quantitative analysis and curve fitting. 50 1.2720nM and 0.7445nM respectively.

[0399] Table 13: Fluorescence intensity analysis of TF01 competitive binding to 293T-TIGIT surface antigen detected by FACS

[0400] The results showed that TF01 antibody could effectively block the binding of CD155 and / or CD112 to TIGIT on the surface of 293T-TIGIT host cells in a dose-dependent manner.

[0401] Example 12: Affinity detection of TF01 and Fc receptor FcγRI

[0402] The Fc receptor FcγRI (also known as CD64) binds to the Fc terminus of IgG antibodies and participates in antibody-dependent cell-mediated cytotoxicity (ADCC). The ability of therapeutic antibodies to bind to Fc receptors influences their safety and efficacy. In this study, the affinity constant of TF01 for FcγRI was measured using the Fortebio Octet molecular interaction instrument to evaluate the antibody's ADCC activity.

[0403] The experimental method for detecting the affinity constant of the corresponding antibody and FcγRI using the Fortebio Octet molecular interaction instrument is briefly described as follows: the sample dilution buffer is PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. A solution of FcγRI (purchased from Sinobio) with a concentration of 1 μg / mL is added to the HIS1K sensor and fixed for 50 seconds to allow FcγRI to be fixed to the sensor surface. The binding and dissociation parameters of the antibody and FcγRI are determined in buffer, with the antibody concentration ranging from 3.12 to 50 nM (two-fold gradient dilution). The sample plate vibration rate is 1000 rpm, the detection temperature is 30°C, and the frequency is 5.0 Hz. The data are analyzed using a 1:1 model fit to obtain the affinity constant.

[0404] The results of the affinity constant determination between FcγRI and TF01 are shown in Table 14 and Figures 11 and 12 .

[0405] Table 14: Kinetic parameters of TF01 binding to FcγRI

[0406] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0407] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRI with an affinity constant of 6.51E-09M. Since TF01 did not bind to FcγRI or the binding signal was extremely low, the results were not analyzed and no corresponding data were obtained.

[0408] The results showed that the binding activity of TF01 to FcγRI was effectively abolished.

[0409] Example 13: Affinity determination of TF01 for Fc receptor FcγRIIIa and its subtypes

[0410] (1) Determination of affinity constants between FcγRIIIa_V158 and TF01

[0411] The Fc receptor FcγRIIIa_V158 (also known as CD16a_V158) binds to the Fc terminus of IgG antibodies, mediating ADCC. The affinity constant between TF01 and FcγRIIIa_V158 was measured using the Fortebio Octet Molecular Interaction Analyzer to evaluate the antibody's ADCC activity.

[0412] The experimental method for measuring the affinity constants of the corresponding antibodies using the Fortebio Octet molecular interaction instrument is briefly described as follows: Sample dilution buffer was PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIIa_V158 was immobilized on the HIS1K sensor for 60 seconds. The sensor was allowed to equilibrate in the buffer for 60 seconds. The sensor-immobilized FcγRIIIa_V158 was then bound to various antibodies at concentrations ranging from 31.25 to 500 nM (two-fold dilutions) for 60 seconds. The antibodies were then allowed to dissociate in the buffer for 60 seconds. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were fit to a 1:1 model to determine the affinity constants.

[0413] The results of the affinity constant determination between FcγRIIIa_V158 and TF01 are shown in Table 15 and Figures 13-14.

[0414] Table 15: Kinetic parameters of TF01 binding to FcγRIIIa_V158

[0415] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0416] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRIIIa_V158 with an affinity constant of 5.54E-08M. TF01 did not bind to FcγRIIIa_V158 or the binding signal was extremely low, so the results were not analyzed.

[0417] The results showed that the binding activity of TF01 to FcγR IIIa_V158 was effectively abolished.

[0418] (2) Determination of affinity constants between FcγRIIIa_F158 and TF01

[0419] The Fc receptor FcγRIIIa_F158 (also known as CD16a_F158) binds to the Fc terminus of IgG antibodies, mediating ADCC. This experiment used the Fortebio Octet Molecular Interaction Analyzer to measure the affinity constant between TF01 and FcγRIIIa_F158 to evaluate the ADCC activity of each antibody.

[0420] The affinity constants of TF01 and FcγRIIIa_F158 were determined using the Fortebio Octet molecular interaction instrument. The experimental method is briefly described as follows: Sample dilution buffer consisted of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIIa_F158 was immobilized on the HIS1K sensor for 120 seconds. The sensor was allowed to equilibrate in the buffer for 60 seconds. The immobilized FcγRIIIa_F158 was then allowed to bind to various antibodies at concentrations ranging from 31.25 to 500 nM (two-fold dilutions) for 60 seconds. The antibodies were then allowed to dissociate in the buffer for 60 seconds. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were fitted with a 1:1 model to determine the affinity constants.

[0421] The results of the affinity constant determination between FcγRIIIa_F158 and TF01 are shown in Table 16 and Figures 15 and 16 .

[0422] Table 16: Kinetic parameters of TF01 FcγRIIIa_F158 binding

[0423] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0424] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRIIIa_F158 with an affinity constant of 9.97E-08M. TF01 did not bind to FcγRIIIa_F158 or the binding signal was extremely low. The results were not analyzed, so the corresponding data could not be obtained.

[0425] The results showed that the binding activity of TF01 to FcγRIIIa_F158 was effectively abolished.

[0426] Example 14: Affinity determination of TF01 for Fc receptor FcγRIIa and its subtypes

[0427] (1) Determination of affinity constants between FcγRIIa_H131 and TF01

[0428] The Fc receptor FcγRIIa_H131 (also known as CD32a_H131) binds to the Fc terminus of IgG antibodies and participates in antibody-dependent cell-mediated cytotoxicity (ADCC). The ability of therapeutic antibodies to bind to Fc receptors influences their safety and efficacy. In this experiment, the affinity constants of TF01 and FcγRIIa_H131 were measured using the Fortebio Octet Molecular Interaction Analyzer to evaluate the Fc receptor binding ability of each test antibody.

[0429] The affinity constants of TF01 and FcγRIIa_H131 were determined using the Fortebio Octet molecular interaction instrument. The experimental method is briefly described as follows: Sample dilution buffer consisted of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIa_H131 was immobilized on an NTA sensor at a height of approximately 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds. The immobilized FcγRIIa_H131 then bound to various antibodies at concentrations ranging from 12.5 to 200 nM (two-fold serial dilutions) over 60 seconds, followed by 60 seconds of antibody dissociation in the buffer. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were fit to a 1:1 model to determine affinity constants.

[0430] The results of affinity constant determination between FcγRIIa_H131 and TF01 are shown in Table 17 and Figures 17 and 18 .

[0431] Table 17: Kinetic parameters of TF01 binding to FcγRIIa_H131

[0432] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0433] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRIIa_H131 with an affinity constant of 3.90E-08M. TF01 did not bind to FcγRIIa_H131 or the binding signal was extremely low. The results were not analyzed, so the corresponding data could not be obtained.

[0434] The results showed that the binding activity of TF01 to FcγRIIa_H131 was effectively abolished.

[0435] (2) Determination of affinity constants between FcγRIIa_R131 and TF01

[0436] The Fc receptor FcγRIIa_R131 (also known as CD32a_R131) binds to the Fc terminus of IgG antibodies and participates in antibody-dependent cell-mediated cytotoxicity (ADCC). The ability of therapeutic antibodies to bind to Fc receptors influences their safety and efficacy. In this experiment, the affinity constants of TF01 and FcγRIIa_R131 were measured using the Fortebio Octet Molecular Interaction Analyzer to evaluate the binding ability of each test antibody to the Fc receptor.

[0437] The affinity constants for TF01 and FcγRIIa_R131 were determined using the Fortebio Octet molecular interaction instrument. The experimental method is briefly described as follows: Sample dilution buffer consisted of PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIa_R131 was immobilized on an NTA sensor at a height of approximately 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds. The immobilized FcγRIIa_R131 then bound to various antibodies at concentrations ranging from 12.5 to 200 nM (two-fold serial dilutions) over 60 seconds, followed by 60 seconds of antibody dissociation in the buffer. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were fitted with a 1:1 model to determine affinity constants.

[0438] The results of affinity constant determination between FcγRIIa_R131 and TF01 are shown in Table 18 and Figures 19 to 20 .

[0439] Table 18: Kinetic parameters of TF01 binding to FcγRIIa_R131

[0440] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0441] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRIIa_H131 with an affinity constant of 3.22E-08M. Since TF01 did not bind to FcγRIIa_R131 or the binding signal was extremely low, the results were not analyzed and therefore no corresponding data were obtained.

[0442] The results showed that the binding activity of TF01 to FcγRIIa_R131 was effectively abolished.

[0443] Example 15: Determination of affinity constants between FcγRIIb and TF01

[0444] The Fc receptor FcγRIIb (also known as CD32b) binds to the Fc terminus of IgG antibodies. This experiment used the Fortebio Octet Molecular Interaction Analyzer to measure the affinity constants of each test antibody for FcγRIIb to evaluate TF01's ability to bind to Fc receptors.

[0445] The affinity constants for TF01 and FcγRIIb were determined using the Fortebio Octet molecular interaction instrument. The experimental method is briefly described as follows: Sample dilution buffer consisted of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 5 μg / mL FcγRIIb was immobilized on an NTA sensor at a height of approximately 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds. hFCGR2B-his, immobilized on the sensor, was then allowed to bind to various antibodies at concentrations ranging from 12.5 to 200 nM (two-fold serial dilutions) for 60 seconds. The antibodies were then allowed to dissociate in the buffer for 60 seconds. The sample plate was shaken at a rate of 1000 rpm, the detection temperature was 30°C, and the frequency was 5.0 Hz. Data were fit to a 1:1 model to determine affinity constants.

[0446] The results of the affinity constant determination between FcγRIIb and TF01 are shown in Table 19 and Figures 21 and 22 .

[0447] Table 19: Kinetic parameters for binding of TF01 to FcγRIIb

[0448] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0449] The results showed that 26B12H2L2 (hG1WT) could bind to FcγRIIb with an affinity constant of 4.12E-08M. Since TF01 did not bind to FcγRIIb or the binding signal was extremely low, the results were not analyzed and therefore no corresponding data were obtained.

[0450] The results showed that the binding activity of TF01 to FcγRIIb was effectively abolished.

[0451] Example 16: Determination of affinity between TF01 and C1q

[0452] Serum complement C1q can bind to the Fc terminus of IgG antibodies, mediating the CDC effect. The ability of therapeutic antibodies to bind to C1q affects their safety and efficacy. In this experiment, the affinity constant of TF01 for C1q was measured using the Fortebio Octet Molecular Interaction Analyzer to evaluate the CDC activity of these antibodies.

[0453] The experimental method for measuring the affinity constants of the corresponding antibodies for C1q using the Fortebio Octet molecular interaction instrument is briefly described as follows: Sample dilution buffer consisted of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 50 μg / mL of antibody was immobilized on a FAB2G sensor at a height of approximately 2.0 nm. The sensor was equilibrated in the buffer for 60 seconds. The immobilized antibody then bound to the antigen C1q at a two-fold serial dilution rate of 0.625–10 nM over 60 seconds, followed by 60 seconds of antigen-antibody dissociation in the buffer. The sample plate was shaken at 1000 rpm, the detection temperature was 30°C, and the detection frequency was 5.0 Hz. Data were analyzed using a 1:1 model fit to obtain affinity constants. Data acquisition and analysis software were Fortebio Data Acquisition 7.0 and Fortebio Data Analysis 7.0.

[0454] The results of the affinity constant determination between TF01 and C1q are shown in Table 20 and Figures 23 and 24 .

[0455] Table 20: Kinetic parameters of TF01 binding to C1q

[0456] N / A means that the antibody did not bind to the antigen or the binding signal was extremely low, and the result was not analyzed, so the corresponding data could not be obtained.

[0457] The results showed that 26B12H2L2 (hG1WT) could bind to C1q with an affinity constant of 1.28E-09M. Since TF01 did not bind to C1q or the binding signal was extremely low, the results were not analyzed and no corresponding data were obtained.

[0458] The results showed that the binding activity of TF01 to C1q was effectively abolished.

[0459] Example 17: Antibody-mediated phagocytic activity of TF01 antibody on CHO-K1-TIGIT cells

[0460] To detect antibody-dependent cellular phagoxytosis (ADCP) activity, mouse macrophages were used as effector cells and TIGIT-overexpressing cell lines were used as target cells to examine the ADCP effect mediated by them.

[0461] Take frozen MBMM (mouse bone marrow-derived macrophages) (derived from C57 mice), add DMEM + 10% FBS + 100 ng / mL M-CSF (macrophage colony-stimulating factor, Peprotech, product number: 315-02), centrifuge at 1200xg for 5 minutes, collect the cells, add DMEM + 10% FBS + 100 ng / mL M-CSF culture medium, and revive overnight.

[0462] Target cells (CHO-K1-TIGIT) were collected, centrifuged at 170xg for 5 min, and washed once with PBS. Trypan blue was counted, and CFSE (5(6)-carboxyfluorescein diacetate succinimidyl ester, Biolegend, Cat. No. 423801) was diluted to 2.5 μM with PBS. An appropriate amount of diluted CFSE was taken to resuspend the cells (staining density: 1x10 7 cells / mL), placed in an incubator and incubated for 20 minutes; added 6 mL of DMEM complete medium (containing 10% FBS) to terminate the staining, centrifuged at 170xg for 5 minutes, and discarded the supernatant; added 1 mL of DMEM complete medium, placed in an incubator and incubated for 10 minutes; diluted the antibody to the required concentration with DMEM complete medium, and designed an isotype control antibody; the target cells (1.5x10 5 / well) were added to a 96-well conical bottom plate, and the antibody (100 μL) was added and mixed, incubated on ice for 40 min, and washed twice by centrifugation at 170×g for 5 min; macrophages (MBMM) were collected and centrifuged at 750×g for 5 min, the supernatant was discarded and counted, and the cells were resuspended in DMEM complete medium to adjust the concentration of macrophages (5×10 4 100 μL of PBSA was added to each well of a 96-well conical-bottom plate containing target cells, resuspended and mixed, and incubated in a 37°C incubator for 2 hours. 100 μL of room-temperature 1% PBSA was added to each well, centrifuged at 750 x g for 5 minutes, and the supernatant was discarded. The cells were washed once with 200 μL of PBSA. 100 μL / well of APC anti-mouse / human CD11b antibody (Biolegend, Cat. No. 101212) (500-fold diluted in PBSA) was added to the corresponding samples, mixed, and incubated on ice for 40 minutes. 100 μL of 1% PBSA was added to each well, centrifuged at 750 x g for 5 minutes, and the supernatant was discarded. The cells were washed once with 200 μL of PBSA per well. The cells were resuspended in 200 μL of 1% PBSA per tube and loaded onto the instrument. Macrophages in the loading system are APC-positive, while phagocytic macrophages are both APC- and CFSE-positive. The ratio of double-positive cells to APC-positive cells was used as the phagocytic rate, which was then used to evaluate the antibody-mediated ADCP activity. The ADCP activity of each group was calculated according to the following formula and expressed as P%:

[0463] The results are shown in Figure 25.

[0464] The results showed that RG6058 (hG1WT), RG6058 (hG4), and 26B12H2L2 (hG1WT) had ADCP effects at the same concentrations; the phagocytic rate of TF01 at the same concentrations was comparable to that of the isotype control antibody group, indicating that TF01 did not have ADCP effects.

[0465] The results showed that the amino acid mutations introduced into TF01 could effectively eliminate its ADCP effect.

[0466] Example 18: Evaluation of the blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on IL-2 secretion in CD112 / CD155 inhibitory co-culture system

[0467] 1. Evaluation of the blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on CD112 inhibition of IL-2 secretion in Jurkat-TIGIT and THP-1 cell co-culture system

[0468] 2 μg / mL anti-human CD3 antibody (Kongfang Biopharmaceuticals, batch number: 20170830) was coated on a 96-well plate (Corning, model: 3599) at 37°C for 2 h. The coating solution was removed and the cells were washed once with pre-cooled PBS (300 μL). Jurkat-TIGIT cells (Kongfang Biopharmaceuticals) were counted and 5×10 cells were seeded per well of the 96-well plate. 4 cells; antibodies were added according to the experimental design and incubated at 37°C for 30 min; CD112-hFc (Kongfang Biopharmaceuticals, batch number: 20180209) was added according to the experimental design; THP-1 cells (purchased from the Chinese Academy of Sciences, catalog number: 3131C0001000700057) were counted and 5x10 cells were seeded into each well of a 96-well plate. 4 The cells were placed in an incubator and cultured for 48 h. The culture supernatant was collected and the IL-2 content was detected using an IL-2 ELISA kit (Dakoway, catalog number: 1110202).

[0469] The results are shown in Figure 26. The results show that CD112 has a significant inhibitory effect on IL-2 secretion. Antibodies 26B12H2L2 (hG4DM), TF01, TF02, RG6058 (hG1DM), and RG6058 (hG4) all effectively blocked CD112's inhibitory effect on IL-2 secretion in the system, with TF01 and TF02 showing stronger activity than the positive control antibodies RG6058 (hG1DM) and RG6058 (hG4).

[0470] 2. Evaluation of the blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on CD155 inhibition of IL-2 secretion in Jurkat-TIGIT and THP-1 cell co-culture system

[0471] 2 μg / mL anti-human CD3 antibody (Kongfang Biopharmaceuticals, batch number: 20170830) was coated on a 96-well plate (Corning, model: 3599) at 37°C for 2 h. The coating solution was removed and the cells were washed once with pre-cooled PBS (300 μL). Jurkat-TIGIT cells (Kongfang Biopharmaceuticals) were counted and 5×10 cells were seeded per well of the 96-well plate. 4 cells; antibodies were added according to the experimental design and incubated at 37°C for 30 min; CD155-hFc (prepared by Kangfang Biotechnology, batch number: 20180209) was added according to the experimental design; THP-1 cells (purchased from the Chinese Academy of Sciences, catalog number: 3131C0001000700057) were counted and 5x10 cells were seeded into each well of a 96-well plate. 4 The cells were placed in an incubator and cultured for 48 h. The culture supernatant was collected and the IL-2 content was detected using an IL-2 ELISA kit (Dakoway, catalog number: 1110202).

[0472] The results are shown in Figure 27. The results show that CD155 has a significant inhibitory effect on IL-2 secretion. Antibodies TF01 and RG6058 (hG1DM) can effectively block the inhibition of CD155 on IL-2 secretion in the system, and their activities are comparable.

[0473] Example 19: Evaluation of the biological activity of the fusion protein of anti-TIGIT antibody and TGF-βR in promoting IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system

[0474] Jurkat-TIGIT cells (Akeso Biotech) and HT1080-aCD3scFv cells (Akeso Biotech) in the logarithmic growth phase were collected and counted. Jurkat-TIGIT cells were counted at 5×10 cells per well. 4 HT1080-aCD3scFv cells per well, 1x10 4 cells; added diluted antibodies (antibody gradient 3nM, 30nM, 300nM); added soluble anti-human CD28 antibody (3μg / mL) (R&D, catalog number: MAB342-500); cultured in an incubator for 48h; collected the culture supernatant and detected the IL-2 content using an IL-2 ELISA detection kit (Dakoway, catalog number: 1110202).

[0475] The results are shown in Figure 28.

[0476] The results showed that antibodies TF01, TF02 and RG6058 (hG4) could effectively promote IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system, and their activities were comparable.

[0477] Example 20: Evaluation of the blocking activity of the fusion protein of anti-TIGIT antibody and TGF-βR on the secretion of IFN-γ by the TGF-β1 inhibitory system during the secondary immune response of PBMC to CMV antigen

[0478] PBMC (from healthy donors) were revived and inoculated in complete medium (RPMI 1640 + 10% FBS) in an incubator overnight. The next day, cells were collected, counted, and viability was calculated. 2x10 5 Cells were seeded per well in a round-bottom 96-well plate (Corning, Catalog No. 3799). Serially diluted antibodies, CMV (final concentration 0.02 μg / mL, Mabtech, Catalog No. 3619-1), and TGF-β1 (final concentration 3 ng / mL, Genscript, Catalog No. Z03411) were added simultaneously according to the experimental design to a final volume of 200 μL. (TGF-β1 and antibody were incubated at 37°C for 10 min). The cells were cultured in an incubator for 4 days. After 4 days, the cell culture supernatant was collected and IFN-γ levels were measured using an IFN-γ ELISA kit (Dakoway, Catalog No. 1110002).

[0479] The results are shown in Figure 29. The results demonstrate that CMV antigens can induce IFN-γ secretion in PBMCs as a secondary immune response, and TGF-β1 significantly inhibits IFN-γ secretion. Antibody TF01, anti-HEL & TGFβ, and the combination of anti-HEL & TGFβ + 26B12H2L2 (hG1DM) all effectively blocked TGF-β1's inhibitory effect on IFN-γ secretion, whereas 26B12H2L2 (hG1DM) alone was ineffective. TF01's blocking activity was superior to that of the control antibody anti-HEL & TGFβ and comparable to that of the combination of anti-HEL & TGFβ + 26B12H2L2 (hG1DM).

[0480] Example 21: Pharmacodynamic evaluation of anti-TIGIT antibody and TGF-βR fusion protein in a mouse tumor cell subcutaneous transplantation model

[0481] To detect the in vivo tumor inhibitory activity of the fusion protein of anti-TIGIT antibody and TGF-βR, MDA-MB-231 cells (purchased from ATCC) were first inoculated subcutaneously into the mammary fat pad of female Scid Bseige mice aged 6.71-9.57 weeks (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). 17 days after inoculation, the mice were randomly divided into 3 groups according to the tumor volume, with 8 mice in each group. Each mouse was intraperitoneally injected with human peripheral blood mononuclear cells (hPBMC) and administered, and the day of grouping was defined as D0. The administration method was intraperitoneal injection, once a week, for a total of 6 times. hPBMC was injected intraperitoneally on the 8th day after grouping. The modeling and specific administration methods are shown in Table 21. After administration, the length and width of the tumor in each group were measured, and the tumor volume was calculated.

[0482] Table 21: Dosing regimen of anti-TIGIT antibody and TGF-βR fusion protein for the treatment of Scid Beige mouse MDA-MB-231 xenograft tumor model

[0483] The results are shown in Figure 30. The results showed that compared with the isotype control antibody, the anti-TIGIT antibody and TGF-βR fusion protein TF01 can effectively inhibit the growth of mouse tumors.

[0484] In addition, as shown in Figure 31, the tumor-bearing mice had good tolerance to the test drug TF01, and each group had no effect on the body weight of the tumor-bearing mice.

[0485] Example 22: Evaluation of the biological activity of the fusion protein of anti-TIGIT antibody and TGF-βR in promoting IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system

[0486] Jurkat-TIGIT cells (Akeso Biotech) and HT1080-aCD3scFv cells (Akeso Biotech) in the logarithmic growth phase were collected and counted. Jurkat-TIGIT cells were counted at 5x10 per well. 4 HT1080-aCD3scFv cells per well, 1x10 4 cells; added diluted antibodies (final antibody concentrations of 3 nM, 30 nM, and 300 nM); added soluble anti-human CD28 antibody (3 μg / mL) (R&D, catalog number: MAB342-500); cultured in an incubator for 48 h; collected the culture supernatant and detected the IL-2 content using an IL-2 ELISA detection kit (Dakoway, catalog number: 1110202).

[0487] The results are shown in Figure 32.

[0488] The results showed that antibodies TF01A, TF01G, TF01T, TF01t31 and TF01t37 could effectively promote IL-2 secretion in the Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system, and their activity was comparable to that of TF01.

[0489] Example 23: Neutralization of TGF-β Inhibition of IL-4-Induced TF-1 Cell Proliferation by Anti-TIGIT Antibody and TGF-βR Fusion Protein

[0490] TF-1 cells (purchased from ATCC, catalog number: CRL-2003) were collected, centrifuged at 110×g for 5 min, washed twice with assay medium (1640+10% FBS+2.5 g / L glucose), resuspended and counted, and 2×10 4 / 100μL cell suspension; IL-4 (final concentration of 0.1nM) (purchased from Peprotech, catalog number: 200-04), TGF-β1 (final concentration of 3ng / mL) (purchased from Genscript, catalog number: Z03411), TGF-β3 (final concentration of 3ng / mL) (purchased from Peprotech, catalog number: 100-36E), and antibodies (final concentrations of 1000nM, 100nM, 10nM, 1nM, 0.1nM, and 0.01nM) were diluted according to the experimental design; equal volumes of antibodies and TGF-β1 / 3 were added to each well of the eight-well tube, and isotype controls and blank controls were designed, and incubated at room temperature for 30min; then 50μL of the corresponding concentration of antibodies and pre-incubation solution of TGF-β1 and TGF-β3 were added to each well of the 96-well plate, and then 50μL of 0.4nM IL-4, mix well, and incubate in a 37°C, 5% CO2 incubator for 72 hours; after 72 hours, add 20 μL / well CCK-8 (purchased from Japan Tongren, product number: CK04) and incubate in a 37°C, 5% CO2 incubator for 4 hours (observe color changes during incubation); after mixing well, transfer 150 μL to a clean 96-well flat-bottom plate and read the OD value at 450 nm on a microplate reader.

[0491] The results are shown in Figures 33 and 34.

[0492] The results showed that antibodies TF01G, TF01T, TF01t31 and TF01 could effectively neutralize TGF-β1 and TGF-β3 to inhibit IL-4-induced proliferation of TF-1 cells, and their activities were comparable.

[0493] Example 24: Reporter gene experiment in which the fusion protein of anti-TIGIT antibody and TGF-βR blocks the interaction between TGF-β1 / 3 and TGF-βR

[0494] According to the experimental design, antibodies and TGF-β1 / TGF-β3 (prepared at a concentration of 4 ng / mL and a final concentration of 1 ng / mL) were diluted in DMEM+10% FBS medium (TGF-β1 was purchased from Genscript, catalog number: Z03411; TGF-β3 was purchased from peprotech, catalog number: 100-36E). 25 μL of antibody and 25 μL of TGF-β1 / TGF-β3 were added to each well of the 96-well black plate, and isotype controls and blank controls were designed. The cells were incubated at 37°C in a 5% CO2 cell culture incubator for 30 minutes. 293T-TGFβR2-Luc cells (constructed by Kangfang Bio) were collected and resuspended in DMEM+10% FBS medium to count and determine the viability. 5x10 4 Cells / 50 μL of cell suspension were placed in a 37°C, 5% CO2 cell culture incubator and incubated overnight; 50 μL Bright-Glo TM Luciferase Assay Reagent (purchased from Promega, catalog number: E2620) was incubated at room temperature for 30 min; RLU (Relative Light Units) values ​​were read using an Envision multi-label microplate reader.

[0495] The results are shown in Table 22 and Figures 35 and 36.

[0496] Table 22

[0497] The results showed that antibodies TF01G, TF01T and TF01t31 could effectively block the interaction between TGF-β1 / 3 and TGF-βR2, and their activity was comparable to that of TF01.

[0498] Example 25: Reporter gene experiment in which the fusion protein of anti-TIGIT antibody and TGF-βR blocks the interaction between TIGIT and PVR

[0499] CHO-aAPC-PDL1-PVR cells (Akeso Biotech) 2x10 4 Cells / well were seeded in 96-well flat-bottom black plates (Corning, model: 3916) and cultured overnight with 100 μL per well (the culture medium was the growth medium of the cells: Ham F-12 + 10% FBS); the next day, the culture medium in the plate was removed and 1×10 5Jurkat-TIGIT-NFAT-Luc cells (Kongfang Biotech) were added to the cells / well, 50 μL / well (culture medium: 1640 + 10% FBS); antibodies were added at a final concentration of 0.037 nM, 0.37 nM, 3.7 nM, 11.1 nM, 33.3 nM, 100 nM, 300 nM, 1000 nM or 3000 nM) at 30 μL / well, isotype control group and negative control group were set up, the final volume was 80 μL / well, and the cells were placed in an incubator and incubated for 4.5 h; the culture plate was removed, equilibrated to room temperature, and Bright-Glo was added. TM Luciferase Assay System 80 μL / well (purchased from Promega, catalog number: E2650) was used, and the RLU value was read after incubation in the dark for 2 minutes.

[0500] The results are shown in Figure 37.

[0501] The results showed that antibodies TF01G, TF01T, and TF01t31 could effectively block the interaction between TIGIT and PVR, activate the NFAT pathway in effector cells, and activate the expression of luciferase reporter genes, and their activities were comparable to those of TF01, 26B12H2L2 (hG1WT), and 26B12H2L2 (G4DM).

[0502] Example 26: Molecular weight detection of fusion protein of anti-TIGIT antibody and TGF-βR

[0503] The antibody was diluted to 1 mg / ml with 50 mM ammonium bicarbonate (pH 7.8). 50 ml of the diluted sample was digested with 2 μl of PNGase-F (NEB, Catalog No. P0705L) for 1 hour. Then, 10 μl of the digested sample was added to 40 μl of 6 M guanidine hydrochloride (Sigma, Catalog No. V900385-500G) and 5 μl of 0.5 M TCEP (tris(2-carboxyethyl)phosphine, Thermo Fisher, Catalog No. 77720). The mixture was mixed and then denatured and reduced at room temperature for 30 minutes. After separation on a C4 column, the sample was analyzed by mass spectrometry.

[0504] The results are shown in Figures 38 to 43.

[0505] The results showed that the heavy chain of antibody TF01 was broken from 65.7KD to 51.1KD, while the heavy chain of antibody TF01A was slightly broken, while the heavy chains of TF01G, TF01T, TF01t31 and TF01t37 were not broken.

[0506] Example 27: SEC-HPLC detection of fusion protein of anti-TIGIT antibody and TGF-βR

[0507] TF01 and TF01T protein samples were subjected to SEC-HPLC analysis using a UV detector; the detection wavelength was 280 nm; the mobile phase was 25 mM disodium hydrogen phosphate dodecahydrate, 25 mM anhydrous sodium dihydrogen phosphate, 300 mM sodium chloride, pH 6.5; the flow rate was 0.8 mL / min; the injection volume was 100 μg; and the run time was 20 min with isocratic elution.

[0508] The results are shown in Table 23 and Figures 44 to 45.

[0509] Table 23: SEC-HPLC purity test of anti-TIGIT antibody and TGF-βR fusion protein

[0510] The results showed that TF01 had obvious characteristic peaks of degradation fragments, while after mutation modification of TF01T, the degradation problem was solved, the characteristic peaks of degradation fragments disappeared, and the purity of the HPLC main peak was significantly increased.

[0511] Example 28: ELISA method to determine the binding activity of the fusion protein of anti-TIGIT antibody and TGF-βR with TGF-β

[0512] ELISA plates were coated with TGF-β1 at 1 μg / mL and incubated overnight at 4°C. The plate was then washed once with PBST and blocked with 1% BSA in PBS for 2 hours at 37°C. After blocking, the plate was washed three times with PBST. Antibody and TGF-βRII-mFc were serially diluted in PBST. The plate was incubated with the test antibody and TGF-βRII-mFc at 37°C for 30 minutes. After incubation, the plate was washed three times with PBST. After washing, HRP-conjugated goat anti-human IgG (H+L) (Jackson, Cat. No. 109-035-098) and HRP-conjugated goat anti-mouse IgG Fc (Jackson, Cat. No. 115-035-071) secondary antibodies were added at a 1:5000 dilution and incubated at 37°C for 30 minutes. After incubation, the plate was washed four times with PBST. TMB (Neogen, 308177) was then added and color was developed for 5 minutes in the dark. The color reaction was terminated by adding stop solution. The plate was immediately placed in a microplate reader and the OD values ​​of each well were read at 450 nm. Data were analyzed using SoftMax Pro 6.2.1 software.

[0513] The test results are shown in the table.

[0514] Table 24: ELISA detection of the binding of TF01, TF01T, TGF-βRII-mFc and TGF-β1

[0515] The binding efficiency EC of TF01T, TF01, TGF-βRII-mFc (as a positive control) and TGF-β1 was obtained by quantitative absorbance analysis of the bound antibodies and curve simulation calculation. 50 They are 0.100nM, 0.164nM and 0.271nM respectively.

[0516] The results are shown in Figure 46.

[0517] The results showed that TF01T and TF01 had effective binding activity to TGF-β1 in a dose-dependent manner. The results also showed that TF01T, TF01, and TGF-βRII-mFc were all able to effectively bind to TGF-β1, and that TF01T and TF01 had stronger binding abilities to TGF-β1 than TGF-βRII-mFc.

[0518] Example 29: Mixed lymphocyte reaction detection of the biological activity of the fusion protein of anti-TIGIT antibody and TGF-βR in promoting IFN-γ secretion

[0519] Normal human PBMCs (from healthy donors) were isolated and cryopreserved using Ficoll-Paque™ Plus separation medium according to the manufacturer's instructions. After thawing and culturing overnight, suspended cells were removed and adherent cells were added to 1640 complete medium supplemented with GM-CSF (purchased from Peprotech, Catalog No. 300-03) and IL-4 at 2000 U / mL (purchased from Peprotech, Catalog No. 200-04) and cultured in a 37°C, 5% CO2 incubator for three days. The medium was then replaced halfway with 2000 U / mL GM-CSF, 50 ng / mL IFN-γ (purchased from Sinobiological, Catalog No. 11725-HNAS-100), and 100 ng / mL LPS (purchased from SIGMA, Catalog No. L4391), and cultured in a 37°C, 5% CO2 incubator for two days. After two days, induced DCs were harvested and cryopreserved as per standard procedures.

[0520] Two days before the experiment, PBMCs were revived, and 2 hours later, SEB (Staphylococcus aureus enterotoxin antigen, purchased from Toxin technology, catalog number: BT202) with a final concentration of 0.1 μg / mL was added for stimulation and induction for 2 days. On the day of the experiment, PBMCs stimulated with SEB were routinely collected, centrifuged at 250xg for 5 minutes, the supernatant was removed, and the cells were washed once with analysis medium (i.e., RPMI 1640+10% FBS) and resuspended, and counted. On the day of the experiment, DC cells (induced from PBMCs of healthy donors) were revived 2 hours in advance and cultured in a 37°C, 5% carbon dioxide incubator for 2 hours. DCs were collected, centrifuged at 250xg for 5 minutes, the supernatant was removed, the cells were resuspended in analysis medium, and counted. Then, DC cells (1x10 4 / well), PBMC (1x10 5 / well), A549 human lung cancer cells (purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, catalog number: SCSP-503) (2x10 4 Plate cells (40 μL / well) in a 96-well flat-bottom plate. Add 40 μL / well of TGF-β1 at a final concentration of 3 ng / mL and antibodies at final concentrations of 3 nM, 30 nM, or 300 nM to the corresponding experimental wells according to the experimental design. Mix thoroughly and incubate in an incubator for 5 days. After 5 days, collect the supernatant and perform IFN-γ ELISA.

[0521] The results are shown in Figure 47.

[0522] The results showed that compared with the isotype control B12-hG1, antibodies TF01T and 26B12H2L2 (hG1WT) could induce PBMC to further secrete IFN-γ, and the IFN-γ secretion activity of TF01T was stronger than that of the anti-TIGIT monoclonal antibody 26B12H2L2 (hG1WT).

[0523] Although specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details in light of all the teachings disclosed herein, and such modifications are within the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.

Claims

1. A fusion protein comprising: Targeting the first protein domain of immune checkpoints, and The second protein domain has TGF-β binding activity, in, The second protein functional region is a variant of the TGF-βRII extracellular region fragment, and the variant of the TGF-βRII extracellular region fragment is: The first serine at the N-terminus of the TGF-βRII extracellular region fragment is replaced with alanine, glycine or threonine; and / or, the fragment containing the amino acid sequence shown in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular region fragment.

2. The fusion protein according to claim 1, wherein The amino acid sequence of the TGF-βRII extracellular region fragment is shown in SEQ ID NO:33 or SEQ ID NO:

37.

3. The fusion protein according to any one of claims 1 to 2, wherein: The deleted fragment containing the amino acid sequence shown in SEQ ID NO:59 has an amino acid sequence shown in any one of SEQ ID NO:59 to SEQ ID NO:

65.

4. The fusion protein according to any one of claims 1 to 3, wherein: The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO:49 to SEQ ID NO:

58.

5. The fusion protein according to any one of claims 1 to 4, wherein: The immune checkpoints are one or more selected from PD-1, PD-L1, CTLA-4, LAG3 and TIGIT.

6. The fusion protein according to any one of claims 1 to 5, wherein: The first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof.

7. The fusion protein according to claim 6, wherein The anti-TIGIT antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein: The amino acid sequence of HCDR1 is shown in SEQ ID NO:3, the amino acid sequence of HCDR2 is shown in SEQ ID NO:4, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:5, and The amino acid sequence of LCDR1 is shown in SEQ ID NO:8, the amino acid sequence of LCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:

10.

8. The fusion protein according to claim 7, wherein The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is selected from SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17; and The amino acid sequence of the light chain variable region of the anti-TIGIT antibody is selected from SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and SEQ ID NO:

25.

9. The fusion protein according to any one of claims 7 to 8, wherein The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 6; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 11, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 19; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 17, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 19; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 21; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 23; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 21; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 23; The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 11, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 25; or The amino acid sequence of the heavy chain variable region of the anti-TIGIT antibody is shown in SEQ ID NO: 17, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

25.

10. The fusion protein according to any one of claims 7 to 9, wherein: The anti-TIGIT antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single-chain antibody, humanized antibody, chimeric antibody or diabody.

11. The fusion protein according to any one of claims 7 to 10, wherein: The anti-TIGIT antibody includes non-CDR regions, and the non-CDR regions are from a species other than murine, such as from a human antibody.

12. The fusion protein according to any one of claims 7 to 11, wherein The heavy chain constant region of the anti-TIGIT antibody is Ig gamma-1 chain C region or Ig gamma-4 chain C region; the light chain constant region is Ig kappa chain C region.

13. The fusion protein according to any one of claims 7 to 12, wherein: The ability of the fusion protein to bind to the ligand CD155-hFc-Biotin is stronger than that of the control antibody RG6058 (hG4).

14. The fusion protein according to any one of claims 7 to 13, wherein: The fusion protein has an EC of less than 0.08 nM or less than 0.10 nM. 50 Binds to TIGIT-mFc; preferably, the EC 50 Measured by indirect ELISA method.

15. The fusion protein according to any one of claims 7 to 14, wherein: The fusion protein has an EC of less than 0.3 nM, less than 0.4 nM, less than 0.5 nM or less than 0.6 50 Combined with TGF-β1, TGF-β2 or TGF-β3; preferably, the EC 50 Measured by indirect ELISA method.

16. The fusion protein according to any one of claims 7 to 15, wherein The anti-TIGIT antibody is an antibody produced by the hybridoma cell line LT019, and the hybridoma cell line LT019 is deposited in the China Center for Type Culture Collection (CCTCC) with a deposit number of CCTCC NO: C2020208.

17. The fusion protein according to any one of claims 7 to 16, wherein: According to the EU numbering system, When the heavy chain constant region of the anti-TIGIT antibody is IgG1, the heavy chain constant region has one of the following mutation combinations: L234A and L235A; L234A and G237A; L235A and G237A; or L234A, L235A, G237A; When the heavy chain constant region of the anti-TIGIT antibody is IgG4, the heavy chain constant region has one of the following mutation combinations: F234A and L235A; F234A and G237A; L235A and G237A; or F234A, L235A, G237A.

18. The fusion protein according to any one of claims 7 to 17, wherein The amino acid sequence of the heavy chain of the anti-TIGIT antibody is shown in SEQ ID NO:27 or SEQ ID NO:31, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO:

29.

19. The fusion protein according to any one of claims 1 to 18, wherein: The first protein functional region is directly connected to the second protein functional region or connected via a connecting fragment.

20. The fusion protein according to claim 19, wherein The connecting fragment is a polypeptide shown in SEQ ID NO: 69 or SEQ ID NO: 70, or a polypeptide obtained by connecting multiple (e.g., 2, 3, 4, 5 or 6) polypeptides shown in SEQ ID NO: 69 in series, or a polypeptide obtained by connecting multiple (e.g., 2, 3, 4 or 5) polypeptides shown in SEQ ID NO: 69 in series and further connecting with a polypeptide shown in SEQ ID NO: 70 in series; Preferably, the amino acid sequence of the connecting fragment is shown in SEQ ID NO:44 or SEQ ID NO:

66.

21. The fusion protein according to any one of claims 1 to 20, wherein: The first protein functional region and the second protein functional region are independently 1, 2 or more than 2.

22. The fusion protein according to any one of claims 1 to 21, wherein: The second protein functional region is connected to the C-terminus of the first protein functional region.

23. The fusion protein according to any one of claims 7 to 22, wherein The second protein functional region is connected to the C-terminus of the heavy chain of the anti-TIGIT antibody.

24. A fusion protein comprising: Targeting the first protein domain of TIGIT, and A second protein domain having TGF-β binding activity; in, The number of the first protein functional region is 1, and the number of the second protein functional region is 2; The first protein functional region is an anti-TIGIT antibody or an antigen-binding fragment thereof, and the second protein functional region is a variant of a TGF-βRII extracellular region fragment; The amino acid sequence of the heavy chain of the anti-TIGIT antibody is shown in SEQ ID NO: 27 or SEQ ID NO: 31, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 29; The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO:49 to SEQ ID NO:58; The second protein functional region is connected to the C-terminus of the heavy chain of the anti-TIGIT antibody through a connecting fragment; Preferably, the amino acid sequence of the connecting fragment is shown in SEQ ID NO:44 or SEQ ID NO:

66.

25. An isolated nucleic acid molecule encoding the fusion protein of any one of claims 1 to 24.

26. A vector comprising the isolated nucleic acid molecule of claim 25.

27. A host cell comprising the isolated nucleic acid molecule of claim 25, or the vector of claim 26.

28. A conjugate comprising a fusion protein portion and a conjugated portion, wherein: The fusion protein portion is the fusion protein according to any one of claims 1 to 24, and the coupling portion is a detectable label; preferably, the coupling portion is a radioactive isotope, a fluorescent substance, a colored substance or an enzyme.

29. A pharmaceutical composition comprising the fusion protein according to any one of claims 1 to 24 or the conjugate according to claim 28; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients; Optionally, the pharmaceutical composition further comprises one or more tumor chemotherapy drugs.

30. The pharmaceutical composition according to claim 29, wherein The unit dose of the pharmaceutical composition, calculated based on the mass of the fusion protein therein, is 100 mg-1500 mg, 200 mg-1000 mg, 200 mg-800 mg, 300 mg-600 mg, 400 mg-500 mg or 450 mg.

31. Use of the fusion protein according to any one of claims 1 to 24 or the conjugate according to claim 28 in the preparation of a drug for treating or preventing tumors; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

32. The fusion protein according to any one of claims 1 to 24 or the conjugate according to claim 28, for use in treating and / or preventing tumors; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

33. A method for treating or preventing a tumor, comprising the step of administering to a subject in need thereof an effective amount of the fusion protein according to any one of claims 1 to 24 or the conjugate according to claim 28; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphocytic neoplasm, plasma cell cancer, renal cell carcinoma, prostate cancer and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.

34. A variant of the TGF-βRII extracellular region fragment, which is: The first serine at the N-terminus of the TGF-βRII extracellular domain fragment is replaced with alanine, glycine or threonine; or, The fragment containing the amino acid sequence shown in SEQ ID NO: 59 is deleted from the TGF-βRII extracellular region fragment; Preferably, the amino acid sequence of the TGF-βRII extracellular region fragment is as shown in SEQ ID NO:33 or SEQ ID NO:

37.

35. The variant of the TGF-βRII extracellular region fragment according to claim 34, wherein The deleted fragment containing the amino acid sequence shown in SEQ ID NO:59 has an amino acid sequence shown in any one of SEQ ID NO:59 to SEQ ID NO:

65.

36. A variant of the TGF-βRII extracellular domain fragment according to any one of claims 34 to 35, wherein The amino acid sequence of the variant of the TGF-βRII extracellular region fragment is shown in any one of SEQ ID NO:49 to SEQ ID NO:58.